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ABSTRACT 
CELLULAR ZINC TRAFFICKING: THE ZINC PROTEOME 
AND ITS REACTIONS WITH CADMIUM 
 
by 
  
Mohammad Ali Namdarghanbari 
 
The University of Wisconsin-Milwaukee, 2014  
Under the Supervision of Professor David H. Petering  
 
 
 
 Metals play a crucial role in living systems. Iron, zinc, copper, 
molybdenum, and manganese are involved in many essential biological activities. 
Among transition metals, zinc after iron is the most abundant transition metal in 
the human body and the most abundant in the brain. It exists in more than 3000 
proteins, which comprise about 10% of the human proteome. Zn2+ 
dyshomeostasis is associated with chronic diseases such as metabolic 
syndrome, diabetes and related complications, bone loss, growth retardation in 
young children, and neurological and behavioral problems. Despite a good 
knowledge obtained for metabolism of some metal ions such as copper, our 
understanding about Zn2+ trafficking still remains immature. External or internal 
metal ions, which are chemically similar to Zn2+ may disrupt or interfere with the 
process of Zn2+ trafficking and make complications. Metallothionein (MT) and the 
proteome, two major players of cell Zn2+ trafficking, and their metal binding and 
metal exchange reactions with different ligands were studied in this research.  
Metallothionein, a small protein molecule rich in cysteine, binds to seven 
Zn2+ ions with a stability constant of about 1011. A previous study, on the other 
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hand, has reported that one of the seven Zn2+ ions binds to MT with a relatively 
weak binding constant of 108. Purified Zn7-MT extracted from rabbit liver under 
neutral conditions (pH 7) was reacted with different competing ligands and did 
not exhibit such a weak binding affinity to Zn2+ ion. Reaction of Zn7-MT with 
strong acid resulted in the formation of MT* species, which was converted into 
Zn7-MT* upon neutralization and reaction with 7 Zn2+ ions. Zn7-MT* exhibited a 
reactivity of 1 Zn2+ per MT molecule with chelating agents of modest affinity for 
Zn2+ ion. Titration of Zn7-MT with acid to pH 2 or below produced Zn7-MT*, which 
exhibited a biphasic titration curve upon base titration demonstrating the binding 
of 1 Zn2+ ion per MT molecule weakly between pH 5 and 7. Because MT 
generally undergoes acidification during preparation, care must be taken to 
document which form of the protein is present in subsequent experiments at pH 
7. 
Zn-proteome as another significant player in Zn2+ trafficking was studied. It 
has been hypothesized that Zn-proteome has a measurable capacity to bind to 
metal ions such as Zn2+ or Cd2+ through metal ion exchange chemistry.  To test 
this hypothesis the Zn-proteome of pig kidney LLC-PK1 cells was reacted with 
competing ligands such as Zinquin acid (ZQACID), TSQ, EDTA, and apo-MT, 
exhibiting negligible metal exchange reactivity. Reaction of Cd2+ or Zn2+ with the 
Zn-proteome shows that Cd2+ or Zn2+ associates with the proteome and almost 
stoichiometric amounts of Zn2+ become available to react with these chelating 
agents.  The results strongly support the hypothesis that Cd2+ displaces Zn2+ 
from native proteomic binding sites resulting in the formation of  Cd-proteome•Zn 
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species.  Mobilized Zn2+ adventitiously binds to the proteome and becomes 
available to react with the metal binding ligands.  Cd-proteome and Zn-
metallothionein exchange metal ions that increase the possibility that this 
reaction may recover the functionality to the Cd-protein. 
Proteome and supernatant from LLC-PK1 cells were titrated with Zn2+ in 
the presence of zincon (ZI), a relatively weak competing ligand, to study the role 
of Zn-bound proteome in Zn2+ trafficking . Titration curves confirmed that a 
significant amount of unoccupied sites exist within the proteome to bind to metal 
ions. The smaller slope in the second part of the curve compared with the one 
obtained in the titration of ZI with Zn2+ along with the red-shifted absorbance 
spectrum indicate that the formed species are different form Zn-ZI species. We 
hypothesize that these species are ternary adduct complexes, proteome-Zn-ZI. 
Model proteins such as CA, BSA, and trypsin and the fluorescent ligand, TSQ, 
were employed to further investigate this hypothesis. BSA reacted with Zn-ZI and 
the resulted absorbance spectra exhibited a shift in λmax from 620 nm to 640 nm. 
Furthermore, no Zn2+ was released from the product upon size exclusion 
chromatography, indicative of adduct complex formation. In contrast, two other 
proteins, carbonic anhydrase and trypsin did not show any reaction with Zn-ZI 
indicated by lack of change in λmax in their absorbance spectra. The former is a 
Zn-protein without unoccupied Zn2+ binding sites and the latter has neither Zn2+ 
nor documented Zn2+ binding sites. Reaction of TSQ with Zn-ZI also resulted in 
an emission spectrum with a λmax at 470 nm, characteristic of adduct complex 
formation. 
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1. Introduction 
1.1. Zinc, its importance, and regulation in living organisms 
Metals play a crucial role in living systems. About 33% of all proteins have 
metals in their structure and 40% of enzyme-catalyzed reactions engage metals 
such as Fe, Zn, Mg, Mn, Ca, Cu, Co, Ni, Mo, W, Na, K, and V [1]. Iron, copper, 
molybdenum, and manganese are involved in many essential biological redox 
processes such as respiration, photosynthesis, and nitrogen fixation [2]. Like 
prokaryotes, Eukaryote cells rely on metals for many biochemical functions. For 
example, they are highly dependent on Zn containing proteins [3]. Among 
transition metals, Zn after iron is the most abundant transition metal in the human 
body and the most abundant metal in the brain [4]. It exists in more than 3000 
proteins, which comprise about 10% of the human proteome [5]. These proteins 
include 397 hydrolases, 302 lygases, 167 transferases, 43 oxidoreductases, 24 
lyases/isomeases, 957 transcription factors, 221 signaling proteins, 141 
transport/storage proteins, 19 proteins with DNA-repair, replication and translation 
functions, and about 1000 Zn-finger and other Zn proteins with unknown functions. 
[6,7]. As such Zn is involved in a wide range of protein function; it participates in 
more than 300 cellular processes such as DNA transcription, protein synthesis, 
assisting in enzyme structural and catalytic activity, neurotransmission, 
intracellular signaling, and antibiotic activities [8,9]. Disruption of transition metal 
homeostasis in human is involved with pathological conditions in brain, liver and 
kidney. Fe, Cu, and Zn dysregulation has been hypothesized to be associated with 
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Alzheimer disease. [10-12]. Zn deficiency and dyshomeostasis are associated with 
chronic diseases such as metabolic syndrome, diabetes and related 
complications, bone loss, growth retardation in young children, and neurological 
and behavioral problems [13-16].  
Zn2+ binds to proteins with a predominant tetrahedral coordination that can 
be in the form of mononuclear complexes or clusters. Examples of mononuclear 
complexes and Zn clusters are seen in enzymes such as alcohol dehydrogenase 
(ADH) and metallothionein, respectively [17]. Zn2+ exhibits both catalytic and 
structural roles in Zn proteins. Diverse ligand-Zn interactions in the catalytic or 
structural sites of proteins play significant roles in Zn enzyme function or Zn protein 
structure and function. Ligands interact with the metal ion in two coordination 
shells. In the first shell S from cysteine, N from histidine, O from aspartate, 
glutamate or water directly interacts with the metal ion. In the second shell, 
hydrogen bonding of Zn-bound ligands with the surrounding amino acids plays a 
crucial role for the stability of the Zn2+ ligand complex. Figure 1.1. shows different 
modes of interaction between Zn2+ and ligands in the first coordination shell [2, 18]. 
All of these interactions may include formation of Zn bridges between two ligating 
groups. In case of cysteine ligand 1, 2, 3 zinc bridges might form; metallothionein 
clusters (Zn3S9 and Zn4S11) are examples involving formation of 2 and 3 Zn 
bridges. Metallothionein and its clusters will be further discussed in chapter 3.   
Figure 1.2. illustrates how the second coordination shell with the help of hydrogen 
bonding makes a stable complex of Zn2+ in human carbonic anhydrase II. In the 
first shell Zn2+ binds in a tetrahedral coordination to N of 3 imidazole groups from 
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His (94, 96, and 119) and O from a water molecule. In the outer shell 3 His and O-
H make hydrogen bonds to the surrounding amino acids and the protein backbone 
[2]. 
  In Zn enzymes the necessity for flexibility of the the catalytic site toward 
substrate leads to the more dynamic coordination of Zn by ligands from side chains 
of the protein. Therefore, for mononuclear Zn enzymes one or two small molecules 
(e.g. H2O from the surrounding solution) ligate Zn2+. The rest of tetrahedral 
coordination is formed by amino acid side chains (Cys, His, Glu, Asp) ligands. 
Furthermore, such coordination environments might contribute to the reactivity of 
these sites with other metals and therefore metal exchange [2]. On the other hand, 
in structural Zn2+ binding sites there is a full tetrahedral coordination of Zn2+ by 
protein side chains that produces more rigidity and stability in the protein structure. 
These coordination sites commonly involve S4 (4 cysteine sulfhydryl groups), S3N 
(of 3 cysteines and 1 histidine), and S2N2 (of 2 cysteines and 2 histidines) around 
Zn2+. None of these general patterns negates the existence of fully coordinated 
Zn2+ with catalytic activity or partially coordinated Zn2+ with structural properties. 
Examples of these exceptions are tetrathiolate coordinated Zn2+ in Ecoli ada 
protein and structural Zn2+ in hexamer insulin. The former has one loose thiolate 
that contribute to DNA repair (catalytic) [19] and the latter is coordinated with 3 
histidine side chains [20].  
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Figure 1.1. Interaction of Zn with ligands. The first row shows the interaction of S 
from cysteine as the electron donor to Zn2+. In the second and third rows the modes 
of interaction of N from imidazole of histidine and O of glutamate or aspartate (not 
shown) with Zn2+ are displayed (lone pair electrons are not shown) [2, 18]. 
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Figure 1.2. Interaction of Zn2+ and chelating ligands in human carbonic anhydrase 
II. First and second coordination shells are shown [2]. 
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1.2. Metal ion trafficking in cells 
The combination of chemical reactions in living organism that leads to 
cellular influx, distribution, and efflux of metal ions is defined as metal ion 
metabolism or trafficking. Binding of metals by ligands, which are electron donors 
and compete with each other for binding, facilitates metal ion trafficking. There are 
several types of reactions involved in metal ion trafficking that can be listed as 
metal-ligand binding, ligand substitution, metal exchange, and adduct formation. 
Ligands are usually chemical groups on proteins and nucleic acids bearing 
negative charges (phosphate on DNA backbone) or electron lone pairs on donor 
atoms N, O, and S (amine, imidazole, carboxyl, and thiol groups of proteins or N 
and O elements of DNA bases). Influx of the metal ions to the cell occurs through 
different mechanisms such as facilitated diffusion (as the concentration of metal 
outside the cell may be greater than that in the cytosol [17]) involving various metal 
transporters [21-23].  
Metal ions can exist in cytosol in three major forms: tightly or adventitiously 
bound to ligands on proteins or other macromolecules, bound to small molecules 
(e.g. glutathione), and ligated only by water molecules (known as free metal ion). 
Metal ions bound in kinetically labile forms play a significant role in metal trafficking 
within the cytosol. Once the metal reaches the cytosol, it binds to ligands in the 
above mentioned forms. During the last two decades, attempts have made to 
determine the concentration of labile metals in cells by either measuring them 
directly or calculating their concentration using their binding constants to 
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biomolecules [17]. Table 1.1 summarizes the labile concentration of metals in 
eukaryotic cells. 
 
Table 1.1. Estimated concentration of labile metal ions in eukaryotic cells [17]. 
Metal ion Labile ion conentration Organism/Cell type 
Potassium 10-1 M  
Sodium 10-2 M  
Magnesium 10-3 M  
Iron 5 × 10-6 M 
Rat hepatocyte 
(cytosol) 
 11.8 × 10-6 M 
Rat hepatocyte 
(nucleus) 
 9.8 × 10-6 M 
Rat hepatocyte 
(mitochondria) 
Manganese 10-7 M  
Calcium 1-5 × 10-8 M Eukaryote (cytosol) 
Zinc 10-11 M  
 10-12 M Eukaryotic cells 
 < 10-9 M (none) E. coli (bacteria) 
Copper 10-15 M  
 < 10-18 M Yeast 
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Metal trafficking not only contributes to the regulation and distribution of vital 
metals in living cells but also to the toxicity of heavy metal ions such as Cd2+, Pb2+, 
and Hg2+. The therapeutic effect of the complex cis-diamminedichloro-Pt (II) also 
stems from the metal ion trafficking principle. 
Metal ion trafficking in living systems is initiated by metal ions binding to 
ligands as shown in reaction (1).  
M + L          M-L,   K, k1, k-1    (1) 
In this equation K is the chemical equilibrium representing the thermodynamic 
stability of the product complex M-L; k1 and k-1 are rate constants for the formation 
and decay of the product complex, respectively. L is the ligand, which binds to the 
metal ion (M). Another phenomenon that is involved in metal ion trafficking is the 
ligand substitution of the complex M-L that takes place according to the following 
chemical equation.  
M-L + L’          ML’ + L      (2) 
The sequence of metal-ligand binding and ligand substitution in cellular metal ion 
trafficking can be summarized as binding of metal ion to protein transporters in cell 
membrane, substitution of protein transporter with components of the cytoplasmic 
or nuclear proteome or complement of small molecules, and finally ligand 
substitution involving the cytoplasmic proteome and metal-transporter proteins 
responsible for metal efflux.  
M + Transportero     M•Transportero       M-Transporteri   (3) 
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M-Transporteri + L1       ML1 + Transporteri 
ML1 + L2   ML2 
        . 
        . 
        . 
MLn + protein (binding site)        M-protein 
With large binding constants for seven Zn2+ ions and kinetic lability of its two 
thiolate clusters, metallothionein plays a major role in Zn2+ trafficking. 
Metallothionein is also a major protein to traffic Zn2+ between cytoplasm and the 
nucleus [21]. Studies on hepatocytes of Zn2+ injected rats has shown a high Zn2+ 
uptake by their nuclei [24]. Because of low localization of Zn2+ transporters to the 
nuclear membrane and small concentration of free Zn2+ in the cytoplasm, neither 
Zn2+ transporters nor diffusion could be candidates for that observation. Further 
study by other groups has shown that MT is actually responsible for the high zinc 
uptake by the nuclei [25-28].  
Metal-ligand binding and ligand substitution comprise the major chemical 
reactions in normal metal ion trafficking. In addition, metal ion exchange and 
adduct formation can play major roles in special conditions such as exposure of 
cells to toxic metals and ligands. In metal exchange reactions, metals compete to 
bind to the ligand via two groups of reactions shown as following.  
M1-L +M2        M2-L + M1  K, k1, k-1 
M1L1 + M2L2        M2L1 + M1L2     (4) 
The affinity of a ligand toward a specific metal (K) determines formation of 
that metal complex assuming the kinetics of reaction are favorable. Under normal 
10 
 
 
conditions, the specificity of the ligand, which is determined by the kinetics, 
energetics, and mechanism of the reaction, insures that metal ions and ligands 
avoid reactions unrelated to metal trafficking. On the other hand, in case of toxicity; 
ligands might prefer some toxic over essential metals leading to cell injury. 
Another form of ligand-metal binding involves adduct formation. In this type 
of interaction a ternary complex forms among metal and two ligands. The following 
chemical equation represents adduct formation among a metal M, ligand L, and 
ligand L’: 
M-L + L’          L’-M-L     (5) 
One ligand could be the metalloprotein and the other ligand, which should be at 
least bidentate, may be an internal small molecule such as glutathione (GSH) or 
any externally administered ligand. 
1.3. Cadmium trafficking and toxicity 
 Cadmium (Cd) is a heavy metal and one of the major pollutants on earth. 
Cd is widely distributed within the earth crust, but its natural concentration in water, 
soil and atmosphere that mainly originate from weathering of earth minerals, forest 
fires, and volcanoes is too low to be a threat to living systems [29]. During the last 
century due to the human industrial and agricultural activities, the concentration of 
toxic metals in the environment has been increasing. Cigarette smoke, food, 
compounds used in electronics, pigments, alloys, and rechargeable Ni-Cd 
batteries are the major sources of exposure to Cd for humans [30]. In particular, 
Cd can be accumulated in some certain foods such as rice [31], fish [32], and leafy 
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vegetables [29, 33, 34]. Cd is poorly taken up by the digestive tract; however, its 
absorption is efficient in lungs with 50% uptake of inhaled Cd. Therefore, most of 
human exposure to Cd is either through smoking or in the workplace [35, 36]. 
After uptake, Cd2+ is transported and accumulated in the liver, kidney, and 
some other organs, where it causes adverse effects [37-40]. The biological half-
life of Cd2+ in human body is about 20 years [41]. Cd2+ induces reactive oxygen 
species (ROS eg. O2-, H2O2, OH) that result in oxidative stress on normal 
physiological functions in the body [42, 43]. Cd2+-induced ROS damages DNA, 
proteins and lipid structure and function, which leads to cell apoptosis [44-47]. It 
also decreases the concentration of glutathione (a small tripeptide with a SH 
group) resulting in the increase of radical species and carcinogenesis [48]. Cd2+ 
accumulated in the liver and kidney is mostly bound to metallothionein [49-54]. The 
half-life of MT is variable - 18-20 hours for Zn-MT and 3 days for Cd-MT in rodents 
but also depends on the organism, organ, and age [55-59]. 
MT protein synthesis is induced in animals with low doses of Cd2+ [60, 61], 
Zn2+ [62, 63], and other metal ions as well as a variety of organic compounds 
including ethanol [64, 65], and diethylmalate [66, 67]. The transcription factor 
MTF1 is responsible for the induction of MT mRNA upon increase of intracellular 
concentration of heavy metal ions such as Zn+2, Cd2+, and Cu1+[68-70]. 
The well-known and probably the major role of MT is to protect cells against 
toxic metal ions especially Cd2+. Studies with mouse kidney epithelial culture cells 
have shown that there is a strong correlation between MT levels and resistance to 
Cd2+ [71]. MT induction also protects against lethal and hepatotoxic levels of Cd2+ 
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[72]. High level of MT in the livers of newborn animals is also correlated with their 
resistance to Cd2+-induced hepatotoxicity [73, 74] The recombinant sheep gene 
MTII inserted into E. Coli protects against elevated levels of toxic metals including 
Cd2+ [75]. MTI/II null mice display high susceptibility to Cd2+ toxicity such as 
hepatotoxicity, hematotoxity, immunotoxicity and bone toxicity [76]. Median lethal 
dose (LD50) of Cd2+ in MT-null mice decreased seven times in comparison to that 
in wild-type mice [77]. 
The mechanism of Cd2+ toxicity has been studied for many years. Petering 
et al. investigated the mechanism of Cd2+ nephrotoxicity using mouse and pig 
kidney cell models and have proposed the only cause-effect mechanism linking 
Cd2+-binding sites to toxicity [78-80]. Upon exposure of kidney cells to micromolar 
concentrations of Cd2+, they observed down regulation of sodium-dependent 
glucose cotransporter protein (SGLT) and sodium-independent cotransporter 
protein (GLUT) and their corresponding mRNAs [81-83]. After removal of Cd2+ 
from cell culture media, they observed that transcriptional depression was retained 
for at least 48h. In other studies, it was demonstrated that Zn3-Sp1, a common Zn-
finger transcription factor, is involved in down regulation of SGLT1 and 2 upon 
binding to Cd2+ [80, 84]. It was also found that Cd2+ binds to the Zn-finger motif of 
Zn3-Sp1 with a binding constant of 1 order of magnitude higher than that for Zn2+ 
[80].  
In previous studies, Wong and Petering observed the similarity in Cd- and 
Zn-finger stability constants in transcription factor IIIA (TFIIIA) and one of its fingers 
[85]. Krepkiy and Petering compared the NMR spectrum of a Cd- and Zn-finger 
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[86]. While generally similar, Cd2+ binding perturbed the conformation of the 
ligating groups around Cd2+. This shift, in turn, changes the orientation and position 
of the amino acids in the recognition helix with regard to the complementary DNA 
base-pair edges and reduces the binding affinity of Cd2+-finger to its cognate DNA. 
Applying their results to Cdn-Sp1 reduction in the binding of the transcription factor 
to DNA leads to the decrease in mRNA biosynthesis and down regulation of 
transporters SGLT and GLUT, hence nephrotoxicity. In their chemical mechanism, 
Cd2+ displaces Zn2+ from a protein binding site to cause toxicity as in reaction 7. 
Wang et al have reported that rPT cells exposed to Cd2+ display elevation 
of ROS and free calcium and reduction of mitochondrial membrane potential, 
intracellular GSH concentration, and enzymatic activities of Na+, K+-ATPase, 
Ca2+-ATPase, glutathione peroxidase (GSH-Px), catalase (CAT), and superoxide 
dismutase (SOD) [87]. Cd2+ renal toxicity, pancreatic toxicity and hepatotoxicity at 
the cellular and molecular levels have been attributed recently to production of 
ROS species and mitochondrial dysfunction [30, 88, 89]. 
In recent years a phenomenological mechanism that has been proposed 
and studied is the interference of Cd2+ with Zn2+ uptake [90-92] and the Zn 
proteome [93, 94]. From studies of the levels of intracellular ROS, antioxidants, 
enzyme activities, and gene expression in a Zebrafish liver cell line (ZFL), Zhu et 
al. have concluded that toxicity of Cd2+ is at first due to its binding to the proteome 
and interference to many biological activities rather than induction of ROS. Indeed, 
ROS induction might be one of the secondary phenomena within the cascade of 
reactions resulting from Cd2+ binding to the proteome. Their proteomic analysis of 
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Cd2+-exposed ZFL cells showed that 34% of differentially expressed proteins were 
metal binding proteins and 12% were enzymes, which were not involved in redox 
reactions. Twenty percent of analyzed proteins, which exhibited metal ion binding 
properties, were transcription factors, 11% were transporters, and 9% were 
involved in signaling pathways. The carcinogenic effect of Cd has also been 
attributed to the substitution of Cd2+ for Zn2+ in Zn-binding proteins that are 
responsible for nucleotide excision repair, base excision repair, and mismatch 
repair [95]. Does Cd2+ react with enzymes involved in redox reactions, proteins in 
the mitochondria membrane, or other Zn-binding proteins? The questions remain; 
where are those binding sites in the proteome, which react with Cd2+ and what are 
the roles of Zn2+ in those reactions. 
From cellular and molecular perspectives we and others hypothesize that 
Cd2+ first binds to the proteome of the cytosol and other compartments then after 
inducing the biosynthesis of metallothionein, it becomes bound to it [95-97]. 
Hypothetical Cd2+ trafficking can be summarized in the following reactions: 
 Cd+2(out)          Cd+2(in)       (6) 
 Cd+2(in) + (Zn•)proteome            Cd•proteome  +  (Zn2+)  (7) 
 Cd•proteome + (apo-or Zn-)MT          Cd-MT  +  proteome  +  (Zn2+) (8) 
 Cd-MT +  Zn-MT           Cd, Zn-MT     (9) 
After transport into the cytoplasm (reaction 6), Cd2+ binds to the proteome either 
tightly through reaction with native metal (Zn) binding sites or adventitiously to 
other proteins (reaction 7). Transcription factors and regulatory proteins may react 
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with cadmium leading to the induction of MT mRNA transcription and apo-MT 
translation [69, 70, 98]. Upon increase in the concentration of apo-MT, reactions 
(7)-(9) are shifted to the right with a higher production of Cd-MT and Cd,Zn-MT. 
As more Cd2+ binds to MT, enough apo-MT is biosynthesized to exceed the 
amount necessary for Cd2+ binding. As a result Cdn, Zn7-n-MT results through 
exchange of Zn2+ and Cd2+ between Zn7-MT and Cd7-MT. 
(7-n)Zn7-MT + nCd7-MT     7Cdn, Zn7-n-MT  1≤ n ≤ 7  (10)  
1.4. Zn fluorophores and their application in studying Zn-proteome  
 Detection and studying metals especially heavy metals, both free or in 
metalloproteins, requires sensitive (as metals exist in trace concentrations) and 
specific analytical methods. Zn2+, which has a filled set of d orbitals, cannot be 
detected and measured using usual spectroscopic methods such as absorption 
spectrophotometry, nuclear magnetic resonance spectroscopy or electron spin 
resonance spectroscopy. Fluorescence methods, on the other hand, are 
commonly highly sensitive and may be specific, making them suitable for metal 
detection and metalloprotein imaging in vitro and in vivo [99, 100]. Zn fluorophores 
have been widely synthesized and used to study Zn2+ and its physiological 
properties in living cells and tissues [99, 101-104].  
Emily L. Que et al have recently reviewed Zn sensors. Figure 1.3 shows 
some of the most commonly used Zn fluorophores. Fluorescence properties of 
these Zn flurorophores are summarized in Table 1.2 [99]. Reagan McRae et al 
have also recently reviewed in situ imaging of metals in cells and tissues [105].   
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The first fluorophores used to selectively detect Zn2+ were quinoline-based 
fluorophores [105]. Mahannad and Houck used 8-hydroxy–quinoline to detect Zn2+ 
in blood plasma and urine [106]. The problem with 8-hydroxy-quinoline was that 
although it exhibited high fluorescence with Zn2+, it showed only moderate Zn2+ 
specificity and also emitted elevated fluorescence in presence of Mn2+ and Ca2+ 
[107]. Different sulfonamide derivatives of 8-amino-quinoline that affected more 
specific detection of Zn2+ were studied by russian biochemists Toroptsev and 
Eschenko [108-111].  
Among those compounds, 6-methoxy-(8-p-toluenesulfonamido)-quinoline 
(TSQ) gained popularity after Frederickson CJ et al. introduced a histochemical 
method to visualize Zn2+ in the brain. They compared four quinoline-based 
fluorophores in their study and found TSQ to be the most suitable one [112, 113]. 
TSQ was also the first fluorophore to specifically detect Zn2+ in presence of Mn2+ 
and Ca2+. It demonstrated 100 fold increase of fluorescence upon reacting with 
Zn2+. Since then TSQ has been actively used for imaging Zn2+ in cells and tissues 
[114-117]. 
Despite all mentioned advantage of TSQ, it has some disadvantages such 
as low water solubility and low cell membrane permeability. To improve water 
solubility and cell membrane permeability of TSQ, methyl and carboxylate groups 
were added to it and the newly synthesized fluorophores: [2-methyl-8-p-
toluenesulfonamido-6-quinolyloxy]aceticacid and ethyl[2-methyl-8-p-
toluenesulfonamido-6-quinolyloxy]acetate were designated as Zinquin Acid 
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(ZQACID) and Zinquin Ester (ZQEster). ZQACID has more water solubility while ZQEster 
exhibits more cell membare permeability.    
ZQ has high Zn2+ specificity and low toxicity, which makes it a suitable 
fluorophore to study intracellular chemistry of labile Zn2+. ZQ was actually the first 
Zn flurophore that was used for imaging Zn2+ in living cells [118].  ZQACID and 
ZQEster has been intensively used to visualize and detect Zn2+ and Zn-proteins both 
in vivo and in vitro [112, 119-122]. ZQ has been used to study Zn2+ distribution 
among different compartments in cortical neurons [123], to detect Zn2+ in 
glutameric vesicles of the brain [124], in apoptosis studies [122, 125], in pancreatic 
carcinogenic studies [126], and in vitro studies on Zn2+ in normal human prostate 
cells [127].  Petering et al. have used ZQAcid and ZQEster in different invivo and 
invitro studies to study mechanism of Zn2+ imaging in cells and tissues [128, 129]. 
TSQ and ZQ are bidentate ligands and bind to Zn2+ through quinoline and 
sulfonamide nitrogens [114, 130]. Therefore, the stoichiometry of ligand to metal 
binding is 2:1. 
L + Zn2+           ZnL2   (L= TSQ or ZQ)   (11) 
Zn(TSQ)2 or Zn(ZQ)2 emits visible fluorescence light with a λmax at 490 nm upon 
excitation by UV light with the wavelength 365 nm. Traditionally the fluorescent 
image obtained from cell or tissue upon their reaction with Zn fluorophores was 
assumed to originate only from free Zn2+, but recently Petering and Nowakowski. 
have demonstrated that fluorescence emission, depending on the properties of the 
sensor, can come from chelatable and adductable Zn2+ [131]. It has been though 
that there is a possibility that the fluorophore sequesters metals from 
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metalloproteins and therefore interferes with physiological reactions under in vivo 
studies [114].  Upon reaction of the bidentate fluorophore with metalloprotein two 
possible reactions may occur:  
Zn-protein  +  2LBidentate            apo-protein  +  ZnL2   (12) 
Zn-protein  +  2LBidentate          L-Zn-protein  (adduct)   (13) 
In the first reaction metal ion is sequestered by the ligand and the free complex 
ZnL2 is formed that gives a fluorescence spectrum with a λmax at 490 nm. In the 
second reaction an adduct (ternary) complex forms between metalloprotein and 
the bidentate ligand, which gives a fluorescence spectrum with a λmax blushifted to 
470 nm. A spectrum with a λmax at 470 nm and a shoulder at λmax 480 nm indicates 
occurrence of a mixture of both above-mentioned reactions. Fluorophores ZQACID 
and TSQ have been used in this project to study the effect of Cd2+ on the 
distribution of chelatable and adductable Zn2+ in the proteome.  
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  Table 1.2. Fluorescence properties of some common Zn fluorophores [132, 133]. 
 
Probe Kd for Zn2+ 
λexitation, nm, 
free(Zn2+) 
λemission, nm, 
free(Zn2+) 
Cellular/membrane 
partition 
FluoZin-1 7.8 µM 491 520 Impermeable, permeable ester 
FluoZin-2 2.1 µM 492 521 Impermeable, permeable ester 
FluoZin-3 15 nM 492 517 Impermeable, permeable ester 
RhodZin-1 23 µM 548 589 Impermeable, permeable ester 
RhodZin-3 65 nM 545 575 Impermeable, permeable ester 
FuraZin 3.4 µM   378 (330) 550 (550) Impermeable, permeable ester 
TFLZn  360 498 permeable 
 0.55 pM 330 553 (528) permeable 
  345 448 permeable 
 0.5 µM 343 450  
TSQ 10 nMb 365 485 permeable 
ZQACID 85 ± 15 nMa 368 490 Impermeable, permeable ester 
NG-DCF 1 µMb 505 530 Impermeable, permeable ester 
NG-PDX 30-40 µM 491 520 Impermeable, permeable ester 
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Figure 1.3. Structures of Some Common Zn Fluorophores [99]. 
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2. Methods 
 
2.1. Isolation, purification, and characterization of rabbit liver 
metallothionein 
 
2.1.1. Preparation of Rabbit Liver 
 Female New Zealand white rabbits (2.2-2.7 kg) purchased from New 
Franken Research Rabbit Inc. were injected with 2 mL 0.15 M sterile ZnSO4 in 
saline (pH 6.0) every 24 hours for 8 consecutive days. The rabbits were 
anaesthetized in the necropsy room, at least 6 hours after the last Zn-injection by 
an injection of Xylazine (95mg/kg) and ketamine (35mg/kg) followed by a lethal 
dose of sodium pentobarbital (120 mg/kg) into the heart.  The livers were removed 
immediately from the rabbits and washed with cold saline to remove excess blood, 
divided into about 20 g samples and stored at -80 ̊C until further use.  
2.1.2. Isolation of Zn7-MT from liver  
 About 20 g of frozen rabbit liver were thawed and minced into small pieces. 
Then, 200 ml homogenizing buffer was prepared in 5 mM Tris-Cl buffer solution at 
pH 8.0 containing 0.25 M sucrose, 0.01 M 2-mercaptoethanol and 200 μl of phenyl-
methyl-sulphonyl fluoride (PMSF)) saturated solution. Tissue was divided into two 
portions and each portion was mixed with 15 ml cold and degassed homogenizing 
buffer. PMSF-serine protease inhibitor- saturated solution was prepared by 
dissolving excess PMSF powder in 2 ml USP grade (200 proof) ethanol. 2-
Mercaptoethanol and PMSF were added to the homogenizing solution just before 
mixing the minced liver in it. The mixture was homogenized using a Potter 
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Helvansen homogenizer, 50 ml size, for 10 cycles per liver portion. The 
homogenate was centrifuged in the Sorvall highspeed centrifuge in the SS34 rotor 
at 20,000 rpm (48000 g) and the Beckman L-70 ultracentrifuge in the 70TI rotor at 
31,000 rpm (75000g) for 20 and 60 minutes, respectively. The final supernatant 
was divided in half and loaded onto two 2.7×85 cm Sephadex G-75 columns 
equilibrated with degassed and cold 20 mM Tris-Cl, pH 7.4, and 5 mM 2-
mercaptoethanol and eluted with a flow rate of 0.5-0.7 ml/min. at 4 ̊C. Eluted 
fractions in the high molecular weight band coming before hemoglobin were 
collected, referred to as rabbit liver proteome, and stored at –80 ºC. Fractions (4 
ml) of MT were collected after almost the red-color band of hemoglobin was eluted.  
The MT fractions were located by measuring the Zn2+ profile of the eluate. 
Altogether about 1-1.5 liters of MT solution were pooled.  
2.1.3. Separation of MT1 and MT2 
 The two isoforms, MT1 and MT2, were separated by anion exchange HPLC 
using a Protein-PakTM DEAE 5PW 7.5×75 mm column purchased from Waters. 
The pooled MT solutions were loaded onto the column with a flow rate between 1-
1.5 ml/min. Eluted fractions were analyzed to check for the minimum release of Zn 
or MT at this stage. MT was eluted with a gradient of 5-300 mM Tris-Cl at pH 7.4 
in 1ml fractions. MT-containing fractions were determined by measuring the 
concentrations of Zn2+ and thiol as described below and then stored at -20°C for 
future use. 
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2.1.4. Preparation of modified metallothionein (MT*) 
 The reaction of Zn7-MT with H+ was studied.  Concentrated HCl (12 N) was 
added to 1–2 mL of Zn7-MT to a final concentration of 1.2 M HCl, reducing the pH 
to −0.4. The solution was left at low pH for 20 min and then neutralized to pH 7.5 
by titration with 10 N KOH. In other experiments a range of hydrogen ion 
concentrations was used to test the pH dependence of the reaction.  
2.1.5. Acid-base titration of metallothionein 
 Metallothionein in 5 mM Tris buffer solution, pH 7.6, KCl 0.1 M, was titrated 
with HCl solutions of different concentrations down to pH about 2 and then back 
titrated with NaOH solutions with similar concentrations to those of HCl solutions. 
Different concentrations of HCl or NaOH were used to minimize the volume change 
and to optimize the pH change of solution with regard to UV absorption of MT at 
215 nm upon each acid addition. Absorbance at 215 nm was measured in 1cm-
wide quartz cuvette for each pH point.  Titration curves for the forward and 
backward titrations were obtained by plotting absorbance versus pH. 
2.1.6. Preparation of apo metallothionein 
 Apo metallothionein was prepared by acidifying Zn7-MT at pH 2 or 3 
depending on the future reaction it would be used for. After acidification, the 
sample was chromatographed over a 0.5 cm x 25 cm sephadex G-15 column 
equilibrated with degassed 0.01 M HCl and the absorbance of 2-ml fractions was 
measured in the spectrophotometer at the wavelength of 220 nm to locate apoMT 
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fractions. 2 to 3 fractions with the highest apoMT concentration were pooled and 
immediately stored in an anaerobic chamber. Apo MT was characterized by its 
absorbance at 220 nm and SH and Zn analysis.  
 The anaerobic chamber was evacuated and purged with nitrogen gas in an 
anaerobic train consisting of vacuum and Nitrogen-purging lines. An Oxygen 
scrubbing catalyst from BASF was used (at 200°C) to remove any oxygen 
impurities from N2. The BASF catalyst removed oxygen by reaction of Cu at the 
surface of its beads at high temperatures about 200-240°C. BASF catalyst was 
occasionally regenerated using H2 and N2 at high temperatures.   
2.1.7. Characterization of Zn7-MT 
 Isolated MT was characterized by measuring the metal and sulfhydryl 
contents in the sample. The metal concentration was obtained by atomic 
absorption spectrophotometry and the sulfhydryl concentration was determined 
using the 5,5-dithiobis-2-nitrobenzoic acid (DTNB) assay [134]. The concentration 
of MT was also determined spectrophotometrically at 220 nm (ε220=1.59 x 105 
M‾1cm‾1) [135]. The ratio of sulfhydryl to Zn in the purified samples was typically 
2.9±0.1, compared to the theoretical ratio of 20 SH/7 Zn (2.86). 
2.1.8. Characterization of Zn7-MT and Zn7-MT* using various competing ligands 
 H2KTS, ZI, NTA, and FluoZin-3 were used to study the Zn2+ binding 
properties of metallothionein. All of these ligands form one-to-one complexes with 
Zn2+ [136]. Zn-KTS has a pH dependent log stability constant of 5.9 at pH 7.4 and 
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a maximum absorbance at 417 nm with extinction coefficient of 11,300±100 M-1 
cm-1, as determined by titration of the ligand with a standard solution of ZnCl2 [137]. 
Nitrilotriacetic acid (NTA) has an intermediate Zn(II) binding affinity. The log 
apparent stability constant of Zn-NTA at 25º C, pH 7.4, and in 0.1 M KCl has been 
reported as 8.32 [138]. Zn-ZI complex displays a maximum absorbance at 620 nm 
with an extinction coefficient of 23,200 M-1 cm-1.  Its log apparent stability constant 
is 4.9 [139]. FluoZin-3 is a Zn2+ responsive fluorophore with a related log stability 
of 7.8 [140]. 
2.1.8.1. FluoZin-3 
 Native and non-native, modified metallothionein (1.6 µM protein), and ZnCl2 
(1.54 µM) were reacted with FluoZin-3 (5 μM) in 50 mM Hepes buffer, 50 mM KNO
3, pH 7.4 anaerobically.  Fluorescence intensity was measured at 517 nm with 
excitation at 492 nm. In later confirmatory reactions, TCEP, a non-thiol reducing 
agent, substituted for anaerobiosis.  
2.1.8.2. H2KTS  
 H2KTS dissolves in Tris-buffer very slowly; so it was first dissolved in ether 
in a 10- ml Pyrex test tube and vigorously shaken until it was slowly extracted into 
the buffer phase; the ether vapor was removed during shaking. The rendered ether 
was then evaporated with heating between 30-40°C. The concentration of H2KTS 
was determined spectrophotometrically by titrating an aliquot of its solution with a 
Zn standard solution. H2KTS was reacted with MT and MT* anearobically to detect 
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the modestly bound Zn in the modified protein. Reaction products for each reaction 
were monitored in the spectrophotometer at 620 nm.  
2.1.8.3. NTA 
 Modified and normal metallothinein were also reacted with the NTA ligand 
anaerobically or in presence of TCEP and the product solution was loaded on a G-
75 column. G-75 column was previously run under degassed 20 mM Tris-HCl 
buffer, pH 7.4 for at least 2 times of its bed volume.  Fractions were analyzed for 
Zn, SH and protein concentrations.  
2.2. Size exclusion chromatography (gel chromatography) 
 G-75, G-25, and G-15 size exclusion chromatography beads were 
purchased from GE Healthcare Bio-Sciences AB. Beads were soaked in 20 mM 
Tris buffer pH 7.4 or Millipore water at room temperature for 24 hours. Columns 
for G-75 were prepared cutting borosilicate glass to 90 cm lengths and fitting with 
a plastic stopcock at one end. A small piece of soaked glass wool leaded by a long 
glass rod, was fit to the bottom of the column as a stopper. Gel slurry was aspirated 
for typically 40-50 minutes and loaded onto columns slowly using a large transfer 
pipet about 5 ml at a time. Pouring columns was continuous, especially for the 
second half of the columns, in order to achieve homogenously packed columns 
with the optimum separation efficiency. Air bubbles were avoided during pouring. 
Upon completion, buffer reservoirs were connected to the top of the column using 
a length of tygon® flexible plastic tubing. In order to get the complete and fine 
packing, columns were equilibrated with 5 times their bed volume of the degassed 
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buffer, pH 7.4 right after being poured. Samples of 0.5-1.5 ml were typically loaded 
onto the column for separation of high molecular weight proteins (more than 10 
KDa) from metallothionein (6 KDa) and/or low molecular weight species (less than 
1 KDa). Fractions of 1 or 2 ml were collected using a CygentTM fraction collector 
based on optical drop counts.  
2.3. Quantification of sulfhydryl group of proteins (DTNB Assay) 
 Concentration of thiol groups of proteins was measured by applying 5,5-
dithiobis (2-nitrobenzoic acid) (DTNB or Ellman’s reagent) assay[134]. Stock 
solution of 10 mM DTNB in Millipore water was prepared and its pH adjusted to 
6.2-6.4 using Tris powder. Tris increases the pH and solubility of DTNB in water 
because it is only slightly soluble at low pH. The solution was then filtered using 
Whatman #2 filter paper to remove any slight amount of non-dissolved solid DTNB. 
DTNB stock solution was kept in dark for later use up to one month from 
preparation. 
 Sulphhydryl concentration of samples was determined by reacting proteins 
in 1 ml aliquots with 1mM DTNB, vortexing the mixture, and waiting about 50-60 
minutes prior to reading their absorption at 412 nm. Concentrations were obtained 
using the Beer-Lambert law and TNB extinction coefficient of 13,600 M-1cm-1. The 
following scheme shows DTNB reaction with SH, which causes TNB release that 
is detected due to its absorbance at 412 nm. 
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2.4. SDS-PAGE gel electrophoresis 
 SDS-PAGE was carried out on the normal and modified metallothionein in 
order to verify the quality of modified protein versus its normal counterpart. Fifteen 
percent Bis-Tris gel was used for electrophoresis. The wells were rinsed well with 
NuPAGE® MOPS SDS (1X) running Buffer. The gel cassette was then positioned 
in the Invitrogen Xcell SurelockTM Mini-Cell tank and upper and lower chambers 
were filled with the running buffer. The gel was pre-run for 5 minutes and then 
samples were loaded into the wells on top of the gel. Samples were heated at 50 
°C for 15 minutes prior to loading on the gel.  Electrophoresis was performed for 
45-60 minutes at the voltage of 200 V until the bromophenol blue reached almost 
at the end of the gel. Gels were fixed and stained using Bio-Rad BioSafe 
Coomassie blue. 
2.5. Culture of LL-CPK1 cells 
 The LL-CPK1 cell line is commercially available. (transformed renal 
epithelial cells from porcine kidney). This cell line was purchased from the 
American Tissue Culture Company (ATCC CL101) for use in our laboratory 
including this project. Cells, kept at -80 ºC, were thawed and transferred to Media 
culture containing 10% fetal calf serum (FCS) and 50 mg/L of each of penicillin 
and streptomycin antibiotics. Media culture for LL-CPK1 cell, M199- modified by 
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Hepes buffer, Catalogue M2520, was purchased from Sigma. Media was prepared 
in 1 L Milli-Q (18MΩ resistant) purified water and the pH was adjusted to 7.2 using 
2.2 g of sodium bicarbonate and 10 M NaOH.  The media was also supplied with 
50 mg of each penicillin and streptomycin antibiotics. Media was then sterilized 
using sterile 0.45 µm Corning© Bottle-top vacuum filters. Media containing cells 
was incubated in sterile culture flasks in an incubator with 5% CO2, 100% humidity 
at 37ºC. After 48-72 h media was replaced with new media and 4% fetal calf serum 
(FCS). After 6-8 days of supplying cells with this new media every other day, 
confluent cells were harvested either by scraping method or using 1ml of Sigma 
Trypsin-EDTA (10X) in saline to release them from culture plates. Harvested cells 
were divided to grow in experimental cell plates and/or culture flasks. All cells were 
handled under sterile conditions using laminar-flow hood equipped with HEPA 
particle filter, sterile lab wares, and sterile solutions.  
2.5.1. Preparation of cell supernatant 
 Cells collected from 2 flasks through the above mentioned procedure were 
transferred to 200 ml media containing 10% FCS and divided into 20 plastic cell 
plates. Cells were incubated and grown to confluence while supplemented by 10ml 
media and 0.4 ml FCS every 48h. Then, cell plates were removed from the 
incubator; after decanting the media cells were rinsed three times with a lab-made 
saline solution. Saline solution was prepared one gallon at a time by dissolving 
32.3 g NaCl, 25.3 g choline chloride, 4.7 g Na2HPO4, and 1.0 g NaH2PO4 in Milli-
pore (18MΩ resistant) purified water. Cleansed cells were scraped very gently from 
cell plates and transferred to cold Sigma-Dulbecco’s phosphate buffered saline in 
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45 ml plastic centrifuge tubes. After rinsing the plates and draining saline, one plate 
per batch was used for cell count. The cells of that plate were treated with 1ml 
trypsin and incubated 10 minutes. Suspended cells were diluted in 10 ml saline 
solution and counted using hemocytometer. 
  Cells were centrifuged at 680 g for 4 minutes and saline solution was 
decanted. The pellet was re-suspended in small amount of fresh cold saline and 
transferred to small tubes for further centrifugation at 1200 g for another 3 minutes. 
Saline solution was decanted and removed as much as possible and 1ml cold Milli-
pore water added to the tube and vortexed. Vortexed cells were sonicated 
immediately with a flat cold tip for 60 pulses. The homogenate was centrifuged in 
a sorvall high-speed centrifuge in the SS34 rotor at 48,000 g for 20 minutes. The 
supernatant referred to as cell supernatant was loaded on a 80 cm G-75 column. 
2.5.2. Cadmium pyrithione treatment of cell culture 
 Stock solutions of pyrithione and Cd2+ in mM concentrations were prepared 
and filtered using sterile filters (0.45 µm pore diameter) under the laminar hood. 
Certain volumes of stock solutions of pyrithione and Cd were added to M-199 
Hepes modified media (with 10% FCS) in order to reach 3 µM pyrithione and 30 
µM Cd2+. Plates of non-confluent LLC-PK1 cells were treated with the above 
solution for 30 minutes and then the media was removed and cells were rinsed 
three times with DPBS. Cells were supplied with fresh media containing 4% FCS 
and kept in incubator for 4h and 24h (2 or 5 plates for each set). The same number 
of cell plates was taken as control. Sample and control cells were harvested by the 
scraping method and the cytoplasm was collected using the method previously 
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explained with the difference that ammonium acetate was used as the running 
buffer over the G-75 column. Chromatography was carried out under a lamiar flow 
hood. Pellets were also collected for analysis for each set of sample or control 
cells. Pellets were digested in concentrated nitric acid overnight and then diluted 
and filtrated for metal analysis. Metal analysis for the collected fractions and the 
pellet was done using ICP-MS on diluted solutions of samples in 2% HNO3. 
2.5.3. Metal quantification using Inductively Coupled Mass Spectrometer (ICP-MS)  
 Metal analysis of low concentration for samples (ppb level)  was performed 
using a Waters Micromass Platform ICP-MS. Samples for ICP-MS analysis were 
diluted to 4 ml total volume in 2% HNO3 in 8 ml Sarstedt plastic tubes, which were 
previously washed thoroughly with 10% HNO3 to avoid any cross contamination. 
Each run was calibrated using a set of 0, 10, 50, and 100 ppb of Zn or Cd standard 
solutions in 2% HNO3. Sample injection was carried out using auto sampler. 
Nebulizer and Torch gas flows were 0.7-1.2 L/min Ar, and 14-17 L/min Ar, 
respectively. ICP-MS run time for each sample took 1.65 min and the acquisition 
time was 1 min/sample. Susan Krezoski did all ICP-MS metal analyses. 
2.5.4. Bio-Rad DC protein assay 
 The Bio-Rad DC protein assay, a test similar to the Lowry Assay, was used 
to measure protein concentrations. This assay is a colorimetric assay based on 
the reaction between copper and protein. Color development happens after copper 
treated tyrosine, tryptophan, and to lesser extent cystine, cysteine and histidine 
reduces Folin’s reagent (sodium 1, 2-naphthoquinone-4-sulfonate). Reduction of 
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Folin’s reagent produces species with maximum absorption at 750 nm. The 
advantage of using this assay over the Lowry method is that the reaction reaches 
90% completion within 15 minutes in this test and the developed color remains 
stable up to 1 hour. In the assay, 50 µl of either standard or sample solutions were 
mixed with 125 µl of reagent A (alkaline copper solution) and 1 ml of reagent B 
(Folin’s reagent) consecutively followed by 15 minutes incubation before reading 
the absorbance quantities at 750 nm.  
 A standard curve was obtained out of measured absorbances at 750 nm for 
bovine serum albumin (BSA) standard solutions with four different concentrations 
ranging between 1.4 and 0.14 mg/ml. Concentrations of proteins were calculated 
using the standard curve and the corresponding absorbance at 750 nm for their 
diluted solutions. 
2.5.5. Treatment of cell supernatant and proteome with Zn2+ and Cd2+ 
 CdCl2 or ZnCl2 in different concentrations was reacted with cell supernatant 
and proteome. The reaction mixtures were loaded onto a G-75 column and HMW 
and low molecular weight fractions were located using AAS analysis. Fractions 
corresponding to high molecular weight proteins were collected and concentrated 
using an Amicon filtration device with 30,000 D cut off membrane. Concentrated 
Zn- or Cd-loaded proteome was either reacted immediately with competing ligands 
or stored in -80°C for later use. 
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2.5.6. Reaction of Cd-, Zn-loaded, and native proteome and cell supernatant with 
competing ligands  
 Cd- and Zn-proteome were reacted with apo- and Zn7-MT to compare the 
metal lability of Cd-treated proteome with that of the native proteome. Zn and Cd 
loaded proteomes were also reacted with different competing ligands such as 
EDTA, NTA and Zincon (ZI) as well as fluorophores TSQ and ZQACID. Sample 
solutions were loaded on sephadex G-75 column after 30 minutes for gel filtration 
chromatography and 1 ml fractions were collected. The proteome region and LMW 
fractions were located by Zn2+ or Cd2+ analysis and fluorescence measurement 
when TSQ or ZQ was employed.  
2.6. Spectroscopy 
2.6.1. Fluorescence spectroscopy 
 Fluorescence measurement of the fluorophores FluoZin-3, TSQ, and 
ZQACID were carried out with a Hitachi F-4500 fluorimeter.  The excitation 
wavelengths for FluoZin-3, TSQ, and ZQACID were 492 nm, 370 nm, and 365 nm, 
respectively, and emission spectra were obtained over the 400 to 600 nm spectral 
range. Voltage of photomultiplier tube was set at 1200 mV and slits of aperture for 
emission and excitation at 5 nm. Excitation and emission spectra were recorded 
at a speed of 240 nm/min; the instrumental response was set at 0.8 seconds. For 
kinetic measurements of FluoZin-3 fluorescence, intensities were recorded at 517 
nm with a response time 0.8 s, 1 reading/second, and lapse time of 0.2 seconds 
for each reading. 
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2.6.2 Ultraviolet-Visible spectroscopy 
 A Beckman Coulter, DU® 640 spectrophotometer was used to measure the 
absorption spectra of chromophores in samples or absorbances at their λmax. 
Measurement of absorbances over time was used for kinetic studies. One-cm 
quartz or plastic cuivettes were used for UV (200-400nm) and Visible (400-600nm) 
measurements, respectively. The Beer-Lambert Law was applied to determine 
concentration of species based on their measured absorbances. 
A=ɛbc           (14) 
Where,  
A=Absorbance, ε =Extinction Coefficient (M-1Cm-1) and c= Concentration (M) 
2.6.3. Atomic absorption spectroscopy 
 Metal quantification at the ppm levels for samples was done on a GBC 
904AA flame atomic absorption spectrometer equipped with a computer for data 
acquisition and processing. Cd2+ and Zn2+ analysis were the most frequent 
measurements using AAS. Measurements were obtained using a Hollow-cathode 
lamp and a deuterium background lamp. Hollow-cathode lamp current was set at 
8.0 mA and 3.0 mA and slit width at 1.0nm and 0.5 nm for Zn2+ and Cd2+, 
respectively. Zn2+ and Cd2+ absorption intensities were detected at 213.9 nm and 
228.8 nm, respectively. Calibration curves were obtained using 3 concentrations 
0.5, 1, and 2 ppm of standard solutions, which were analytically prepared out of 
1000 ppm standard solutions of Zn2+ and Cd2+ purchased from Fisher Scientific. 
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3. Results 
3.1. Reaction of Fluo-Zin3 with normal and modified Zn7-metallothionein 
3.1.1 Introduction 
 Metallothioneins are a group of small size proteins (about 6 kDa), which are 
structurally unique and functionally complicated. It was Malyuga’s discovery of high 
amount of cadmium accumulation in human kidney in 1941 that attracted scientists 
to investigate Cd2+ in kidney [141]. However, the main reason behind Cd2+ 
accumulation was not revealed until 1957[141], when Margoshes and Vallee 
isolated metallothionein from horse kidney. Since then, metallothioneins have 
been under intensive investigation and research both in vitro and in vivo. There is 
still much ambiguity related to their attributed functions such as cadmium 
detoxification, Zn2+ and copper regulation and metabolism, stress response and 
so on. Studying metal binding properties of metallothionein can provide crucial 
knowledge about its roles in heavy metal detoxification and Zn2+ or copper 
regulation.  
 Mammalian metallothioneins, which belong to class (I) out of three classes 
of metallothioneins, have 61 amino acids, among which 20 amino acids are 
cysteines (Figure 3.1). These cysteine residues are highly conserved in 
mammalian metallothioneins [142] and bind to seven Cd or Zn ions in two 
distinctive clusters. Detailed structure of these two clusters was first reported by 
Otvos and Armitage using 113Cd NMR studies [143]. Thiolate groups of cysteine 
residues bind to the divalent metals as terminal and bridging ligands and form a 
three member (chair-shape M3S9) and a four member (extended chair-shape 
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M4S11) in the N-terminal β-domain and C-terminal α-domain of the protein, 
respectively [144] (Figure 3.2) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Sequence for Cd7-MT from rabbit liver. Cd-S connectivity and position 
of two clusters within the protein are shown [142]. 
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Figure 3.2. Structure of Zn7-MT and its three-member, Zn3S9, and four-member, 
Zn4S11 clusters [145]. Numbers refer to the position of the residue in the amino 
acid sequence. 
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Mammalian metallothionein such as rabbit-liver MT, which was isolated, purified 
and used in this project, has two major isoforms; MT1 and MT2. Because MT2 has 
one more negative charge compared to MT1 [146], it was possible to separate 
them using anion exchange chromatography.  
3.1.2. Metallothioneine as a Zn- trafficking protein 
 Over-expression of mRNA for MT biosynthesis happens upon exposure of 
living cells to excess Zn2+ that results in an increasing concentration of apo-
metallothionein [147]. These observations led to hypotheses about the role of MT 
in Zn trafficking. In one perspective metallothionein might be considered as a 
transient pool that buffers living cells from large changes of free or loosely bound 
Zn2+.  
Apo-MT + 7Zn2+                Zn7-MT       (15) 
On the other hand, it might provide Zn2+ for the biosynthesis of Zn-proteins. 
1/7 Zn7-MT + Apo-protein                  1/7 Apo-MT + Zn-protein (16) 
Here, Apo-protein is assumed to have a higher stability constant, which 
thermodynamically favors reaction 16 [148]. 
3.1.3. Zn7-MT stability constants and the proposed weak binding site 
 MT metal binding properties has been under investigation for many years. 
However a consensus has not been achieved about the mechanism of Zn2+ or 
Cd2+ binding to apo-MT and consequently the formation of α and β clusters. Most 
studies have shown similar stability constants for 7 Zn2+ or 7 Cd2+ binding to 
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metallothionein [149, 150]. In those studies, the method of using competing 
ligands, which have known stability constants with Zn2+ or Cd2+, has been 
employed for the determination of Zn7-MT stability constants. They have reported 
stability constants greater than 1010 and 1013 with Zn2+and Cd2+, respectively, at 
pH 7 and 25°. In contrast, Maret et al recently reported three different kinds of sites 
in Zn7-MT with a difference of up to four orders of magnitude in their stability 
constants with Zn2+ [135].  They attributed the high affinity of metallothionein 
toward Zn2+ to the stability constant 1011.8 for the formation of the four-member 
cluster. On the other hand, they ascribed the capability of metallothionein in 
donating Zn2+ to other ligands under certain conditions, to a weakly bound Zn2+ in 
the 3-member cluster with a stability constant of 107.7. The latter can pave the way 
for MT to donate at least 1 Zn2+ to proteins, which bind Zn2+ with a higher binding 
constant.   
 Apo-MT + 4Zn2+           Zn4-MT           K1-4 = 1011.8    per Zn2+    (17) 
 Zn4-MT + Zn2+           Zn5-MT              K5 = 1010.9   (18) 
 Zn5-MT + Zn2+           Zn6-MT              K6 = 1010.7   (19) 
 Zn6-MT + Zn2+           Zn7-MT       K7 = 107.7    (20) 
The experimental determination of these stability constants began with the 
observation that the fluorescent Zn2+ sensor, Fluo-zin 3, reacts with Zn7-MT to form 
a fluorescent Zn2+ product [135]. The Fluozin-3 structure includes a fluorophore 
linked to a set of amine and carboxylate metal binding ligands with a modest 
stability constant for Zn2+ at pH 7 of 107.8 (Figure 3.3). Data in support of the weak 
stability constants were obtained from two similar experiments. In the first, binding 
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isotherms were fit to the titration of apo-MT with Zn2+ in the presence of FluoZin-3 
and RhodZin-3. The second was based on competition between either FluoZin-3 
or RhodZin-3 and MT for Zn2+. 
Besides their implications for metallothionein as a cellular participant in Zn2+ 
trafficking, the results presented by Maret and Krezel suggest that FluoZin-3 might 
be used to image the presence and intracellular location of Zn7-MT. Considering 
the apparent centrality of MT-bound Zn2+ in cellular Zn2+ trafficking according to 
these authors and others, it was important to reexamine their determination 
whether Zn7-MT contains a weak Zn2+ binding site.  
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Figure 3.3. Chemical Structure of FluoZin-3, cell impermeant (2-[2-[2-[2-[bis(2-
oxido-2-oxoethyl)amino]-5-methoxyphenoxy]ethoxy]-4-(2,7-difluoro-3-oxido-6-
oxo-4a,9a-dihydroxanthen-9-yl)anilino]acetate) 
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3.1.4. Preparation of Zn7-MT from Rabbit Liver 
 Zn7-MT was prepared from rabbit liver as described in the methods section. 
Two peaks were obtained from DEAE chromatography, representing MT1 and 
MT2. In the anion exchange chromatography of MT1 and MT2 after loading the 
protein onto the HPLC column, an ionic gradient was employed to separate these 
isoforms. A typical ionic gradient, which was employed in the isoforms separation 
and depicted as conductivity versus the eluted volume, is shown in Figure 3.4. In 
Figure 3.5 a chromatogram of MT1 and MT2 is shown as an example of several 
such separations, which was carried out during MT preparation. The MT2 fraction 
was characterized for protein content (220 nm absorbance), Zn2+ concentration 
(atomic absorption spectrophotometry) and sulfhydryl concentration (DTNB 
analysis). About 700-800 µg MT2/g liver was isolated and purified from rabbit liver 
in a typical MT preparation. The protein used in this study had a Zn2+/MT ratio of 
6.9±0.2, a SH/MT ratio of 20.5±0.5, and a SH/Zn2+ of 2.9±0.1. These values closely 
agree with the theoretical values of 7, 20, and 2.86, respectively.  
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Figure 3.4. Graph of Conductivity Showing the Ionic Gradient Applied after MT 
pool loaded onto the Protein-PakTM DEAE 5PW 7.5×75 mm Column. The 
separation of MT1 and MT2 took place in an applied ionic gradient with conductivity 
less than 3 μS. 
 
 
Figure 3.5. HPLC Chromatogram of MT1 and MT2 separated on the Protein-PakTM 
DEAE 5PW 7.5×75 mm column 
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3.1.5. Preparation of Zn7-MT* from Zn7-MT 
 Maret et al prepared Zn7-MT* by expressing human MT2 in Escherichia coli 
as an intein fusion protein without addition of metal ions to the growth medium 
[135].  The construct was purified by affinity chromatography and the intein was 
cleaved using 0.1 M DTT. The purified protein was acidified to pH 1 using 1.2 M 
HCl and purified by G-25 chromatography equilibrated with 0.01 M HCl (pH 2). 
Final neutralization was achieved by adding small amounts of apoMT to neutral 
reaction buffer in the presence of Zn2+. In addition, PAGE electrophoresis on MT 
showed its high purity (>95%) based on runs with 2-10 µg of protein. 
 We subjected rabbit liver Zn7-MT2 to acid conditions below pH 1, which 
released all of the bound Zn2+ and then restored the sample to pH 7.4. After this 
acid-base cycle the product, designated as Zn7-MT*, retained its full complement 
of sulfhydryl groups as measured with DTNB. In addition, PAGE electrophoresis 
on MT and MT* showed that they migrated at the same rate on the gel, displaying 
one single band based on runs with 0.2-10 µg of protein (Figure 3.6). Moreover, 
MT and MT* were chromatographed over Sephadex G-15 to further test the quality 
of modified MT in comparison to MT.  Collected protein fractions from this 
experiment exhibited a SH/Zn2+ ratio of 2.9±0.1 for both MT and MT* and appeared 
as single peaks in their chromatograms (Figure 3.7a, b). These results showed 
that MT* did not undergo peptide cleavage, loss of metal or modification of 
sulfhydryl groups. Competing ligands such as FluoZin-3, NTA, and H2KTS were 
then used to compare the Zn2+ binding properties of the native (MT) and modified 
(MT*) protein. 
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Figure 3.6. SDS-PAGE for MT and MT* run with 2-10 μg protein/well.   
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Figure 3.7a. Chromatogram of Zn7-MT chromatographed over 30cm x 1.5 cm 
Sephadex G-15 column. SH and Zn2+ concentration and their corresponding ratios 
for 1-ml fractions are shown. 
 
 
Figure 3.7b. Chromatogram of Zn7-MT* chromatographed over 30cm x 1.5 cm 
Sephadex G-15 column. SH and Zn2+ concentrations and their corresponding 
ratios for 1-ml fractions are shown. 
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3.1.6. Characterization of Zn7-MT and Zn7-MT* Using Various Competing Ligands 
3.1.6.1 FluoZin-3  
 Anaerobic reaction of excess FluoZin-3 with Zn7-MT removed 0.22 µM Zn2+ 
equivalent to 0.14 moles Zn2+ per mole MT after a 120 min incubation period 
(Figure 3.8a). The nearly complete lack of reactivity alerted us to the fact that Zn7-
MT isolated from tissue at pH 7 did not behave as reported by Maret et al [135]. In 
comparison, Zn7-MT* reacted with FluoZin-3 as described by these authors such 
that 1.0 ± 0.07 moles of Zn2+ per mole MT were extracted over the 1 h incubation 
period. Based on calculations using the weak stability constant suggested by Maret 
et al and concentrations of MT and FluoZin-3 used in this experiment, we expected 
removal of 0.81 moles Zn2+ per MT mole by FluoZin-3. Thus 20% more Zn2+ was 
removed than expected by FluoZin-3. This 20% excess reaction can be attributed 
to the removal of Zn2+ from sites with higher binding constants than 107.8. 
 The kinetics of the Zn7-MT* reaction were multi-phasic and could be fit to 
first order kinetic steps including two distinct phases and a possible third very rapid 
reaction phase that comprised about 67% of the overall reaction. (Figure 3.8b) 
This would be consistent with FluoZin-3 easily competing with the first Zn2+ binding 
site in the rapid phase. FluoZin-3 was in sufficient excess so that it would compete 
with the second and third Zn2+ sites, allowing for the appearance of one or possibly 
two slower phases. 
 In order to broadly establish the differential behavior of Zn7-MT and Zn7-
MT*, both proteins were reacted with other ligands that also have modest affinity 
for Zn2+ 
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Figure 3.8a. Reaction of FluoZin-3 with ZnCl2 (■), Zn7-MT (▲) or Zn7-MT*(♦). 
Conditions: 1.6 μM protein (11.2 μM Zn2+), 5.0 μM FZ in anaerobic 50 mM Hepes 
buffer, containing 50 mM KNO3, pH 7.4 at 25 ºC. ZnCl2 concentration, 1.54 μM. 
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Figure 3.8b. Kinetic analysis of reaction of FluoZin-3 with Zn7-MT*, the fast (▲) 
and slow (■) phases are shown. The very fast phase was not analyzed. 
 
3.1.6.2. H2KTS  
 A second ligand, H2KTS, was employed to probe for a modestly bound Zn2+ 
ion in Zn7-MT. H2KTS forms a complex with Zn2+ that is readily detected, 
spectrophotometrically. Figure 3.9 shows the chemical structure of H2KTS.  A 
stock solution of H2KTS was diluted 10 times and titrated with standard solution of 
8.5 mM ZnCl2. Figure 3.10 shows the titration curve for the above mentioned 
titration. Based on the data from titration curve, the concentration of H2KTS stock 
solution and its extinction coefficient were calculated as 2.2 mM and 12,000 M-
1Cm-1, respectively. K(H) for ZnKTS formation was calculated based on the 
following equation: 
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   Figure 3.9. Chemical Structure of H2KTS 
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  K(H)=[Zn-Chelate]/([Zn2+][bis(thiosemicarbazone)]all forms) (21) 
The slope of 2.05 shows that two protons are associated with H2KTS in very close 
agreement with the theoretical equation of pH dependence of K(H). 
  log K(H)=2pH +C        (22) 
In which C is a constant. The pH-dependent formation of ZnKTS was plotted 
versus pH and shown in Figure 3.11.  
 Reaction of H2KTS with MT and MT* showed that they also react differently 
with this ligand. Only an insignificant fraction (0.01 mol Zn2+/mol Zn7-MT) of MT’s 
complement of Zn2+ became bound to this competing ligand after 2 h incubation of 
660 μM H2KTS with 23 μM Zn7-MT (161 μM Zn2+) under anaerobic conditions 
(Figure 3.12). Based on calculation we expected removal of 0.61 mole Zn2+ per 
one mole of Zn7-MT* by H2KTS under the above mentioned conditions. After 2 h, 
0.78 ± 0.06 mol Zn2+/mol MT* was complexed by this ligand, most of it within 10 
min, with the reaction still slowly proceeding at the end of this period. 
 
Figure 3.10. Standard curve of H2KTS titration with Zn2+  
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Figure 3.11. Plot of K (H) versus pH for ZnKTS formation 
 
Figure 3.12. Reaction of H2KTS with Zn7-MT (dashed line) or Zn7-MT* (solid 
line). Conditions: 23 μM protein (161 μM Zn2+), 660 μM H2KTS in 50 mM Hepes 
and100 μM TCEP, containing 50 mM KNO3, pH 7.4 at 25 ºC. 
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3.1.6.3. NTA 
 Both Zn7-MT and Zn7-MT* were reacted with NTA following the approach 
used by Maret et al [135]. Samples were incubated anaerobically with NTA for 2 h 
and then chromatographed over Sephadex G-25 (Figure 3.13 and 3.14).  The 
protein fractions were analyzed for Zn2+ and sulfhydryl concentration and their ratio 
used to assess the state of the protein.  Zn7-MT retained its native ratio of 2.9±0.1, 
whereas, the ratio of MT* protein increased to 3.5±0.2, consistent with the removal 
of 1 Zn2+ per mol MT* (20 SH: 6 Zn2+). 
 
 
 
Figure 3.13. Reaction of NTA with Zn7-MT  
Conditions: 24 μM protein, 168 μM Zn2+, 200 μM NTA in 50 mM Hepes and 480 
μM TCEP, containing 50 mM KNO3, pH 7.4 at 25 ºC. SH (▲); Zn (■). 
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Figure 3.14 Reaction of NTA with Zn7-MT*  
Conditions: 24 μM protein, 168 μM Zn2+, 200 μM NTA in 50 mM HEPES and 480 
μM TCEP, containing 50 mM KNO3, pH 7.4 at 25 ºC. SH (▲); Zn (■). 
 
 
3.1.7. Acid-base Titration of Zn7-MT 
 Zn7-MT* was prepared by acidifying Zn7-MT to about pH 0.4 and then 
restoring the pH to 7.4. It was of interest to examine the acid-base titration 
characteristics of this process.  Typical acid-base titrations of Zn7-MT spanning pH 
7 to 2-3 display a single step of Zn2+ dissociation and re-association and are 
completely reversible. In contrast, with Zn7MT* according to Figure 3.15a, during 
neutralization 2 steps are resolved.  The first step follows the path of the 
acidification and accounts for 85% of the overall change in 215-nm absorbance 
(Zn-sulfhydryl bonding) or 6/7 of the bound Zn2+ assuming a linear relationship 
between Zn2+ and 215-nm absorbance.  The second occurs between pH 5-7 and 
represents a weakly bound fraction of about 1 Zn2+ per mol MT*.  
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The following chemical equation, which assumes equal stability constants 
for all seven Zn2+ ions, represents the single-step acid titration.  
Zn7–MT + mH+             Hm–MT + 7Zn2+    (23) 
Where, m=20 
However the base titration, which is two-step, can be shown by the following 
equations: 
(H(m+n) –MT*) +6 Zn2+ + mOH-            Zn6–MT*-Hn + mH2O    ,m=18-19 (24) 
Zn6–MT*-Hn + Zn2+ + nOH-            Zn7–MT* + nH2O,  ,n=1-2  (25) 
For Cd7-MT, a two-step acid titration curve was obtained indicative of a slight 
difference for stability constants of Cd2+ binding in three-member and four-member 
clusters (Figure 3.15b). Indeed Cd4S11 showed a midpoint for titration at a lower 
pH 3.1 in comparison to Cd3S9, which displayed a midpoint at pH about 3.6. This 
difference became less significant for Cd7-MT*, which instead showed a distinct 
step with a midpoint at a higher pH about 5 for 1 Cd2+. 
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Figure 3.15a. Acid–base titration of Zn7-MT. Acidification with HCl (♦) and 
neutralization with NaOH (■) in 5 mM Tris–Cl buffer, 0.1 M KCl at room 
temperature. 
 
 
Figure 3.15b. Acid–base titration of Cd7-MT. Acidification with HCl (♦) and 
neutralization with NaOH (■) in 5 mM Tris–HCl buffer, 0.1 M KCl at room 
temperature. 
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3.1.8 Kinetics and extent of reaction of Zn7-MT with hydrogen ion 
Zn7-MT was incubated at pH 3, 2.7, 1.8, and 1.0 for a series of times, rapidly 
neutralized, and then reacted with FluoZin-3 as an indicator of the degree of 
conversion of Zn7-MT to Zn7-MT*. Like pH 0.4, the native samples reacted at pH 
1.0 and 1.8 were converted to Zn7-MT* within 20 min. Indeed, at pH 1.0, the 
reaction was complete within 3 min, the quickest time for acidification and 
neutralization. At pH 2.7 and 3.0 the reactions were time dependent. For example, 
the fractional conversion to Zn7-MT* after incubation at pH 2.7 for 20, 60, and 120 
min was 0.68, 0.96, and 1.12 mol Zn2+/mol MT, respectively. (Figure 3.16a) These 
values for pH 3.0 were 0.5, 0.6, and 0.8, respectively. (Figure 3.16b) 
 
Figure 3.16a. Extent of reactivity of MT* with FluoZin-3 after its acidification to pH 
2.7 for 20, 60, 120 min and reneutralizaion. 
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Figure 3.16b. Extent of reactivity of MT* with FZ after its acidification to pH 3 for 
20, 60, 120 min and reneutralizaion 
 
 
3.2. Reaction of proteome and Cell Supernatant with Cd2+ and Zn2+  
3.2.1. Introduction 
 The combination of all proteins working either in assembly or in discrete 
fashion in living cells, tissues, or organisms is called the proteome. The number of 
known proteins in the proteome is increasing as more research detects new 
proteins and finds their functions in living organisms. A significant portion of the 
proteome consists of proteins with at least one metal ion in their structure; 
therefore it is designated as the metalloproteome [151]. Metals in the 
metalloproteome have two major roles; they either take part in the determination 
and/or stabilization of protein structure or contribute directly to protein function, as 
in metalloenzymes. Among metals, transition metals play a crucial role in living 
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cells and their biological activities, despite their existence of trace amounts in living 
organisms. A transition metal with filled 3d orbitals, Zn2+ is the second most 
abundant transition metal ion in living organisms. It has a broad spectrum of 
functionality and a variety of structural binding patterns in proteins. Zn2+ is almost 
spectroscopically invisible; therefore, detecting and studying the role of Zn2+ in Zn-
proteins requires more effort than needed for spectroscopically active-metal 
containing proteins such as iron and copper proteins.  
 Despite the significant amount of research that has been done on Zn2+ in 
living cells, Zn trafficking from outside the cell into the cytosol and its regulation 
inside the cell remain elusive. Previously, Zn-transporters as the suppliers of Zn2+ 
to the cell were largely the focus of study [152]; but the nature of Zn2+ species 
involved in Zn2+ trafficking from the external medium to the binding sites of 
metalloproteins were not addressed. Two main hypotheses suggest that either free 
Zn2+ or ligated Zn2+ is in play with Zn2+ transporter proteins of the cell membrane, 
which carry Zn2+ from outside the cell to the cell cytoplasm [152].  
 Previous studies have shown that pM to nM concentrations of free Zn2+ or 
very loosely bound Zn2+ exist in living cells [153] These low concentrations along 
with the relatively small Km values of Zn-transporters (e.g. Zrt1, 10 nM and Zrt2, 
100 nM) [154]  imply that if free Zn2+ is assumed to be involved in the transport 
processes, Zn-transporters would not be efficient [155]. Furthermore, even 1 
nmolar free Zn2+ would provide only 10% of the Zn demand of cells that divide 
every 24h, assuming cellular Zn-protein concentration of 100 µM and  a highly 
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optimistic second-order rate constant of 108 M-1s-1 for the formation of the Zn-
protein  
  Zn2+ + apo-protein   Zn-protein    (26) 
 The other hypothesis suggests that Zn2+ is transited among different binding 
sites and regulated within the cell through ligand substitution reactions analogous 
to what seen for copper trafficking [156].  Glutathione, metallothionein, and Zn-
proteome are the major Zn-binding pools within the cell that may participate in the 
Zn2+ trafficking. However, the mechanism of this complex process and the explicit 
role of these cellular Zn2+ chelating agents are as yet too complicated to be fully 
understood.  
 The pernicious effects of Cd on human kidney function and bone integrity 
was first noticed in mid twentieth century upon people’s exposure to occupational 
and environmental Cd contaminant in Sweden and Japan, respectively [79, 157]. 
The discovery of metallothionein as a sulfhydryl-rich protein that binds to Cd2+ 
tightly in living organism has formed the majority of the research about Cd2+ 
toxicity.  The main documented function of metallothionein in the literature is also 
about its involvement in Cd2+ toxicity.  Metallothioneins scavenge elevated 
amounts of Cd2+ in tissues and cells by binding tightly to it and therefore buffering 
it from interfering with hundreds of enzymes and thousands of proteins.  Like all 
other proteins there is a balance between biosynthesis and biodegradation of 
metallothionein.  The degredaded MT releases Cd2+, which will be taken mostly by 
the newly synthesized apo-MT. Therefore, under steady state, Cd2+ cannot exist 
as free Cd2+ and will be tightly bound to MT. 
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 Cd-MT → Cd2+ + amino acids → Cd-MT   (27) 
If the rate of biodegradation exceeds the rate of biosynthesis, the newly 
synthesized apo-MT would not be sufficient to take up the Cd2+ released from the 
biodegraded Cd-MT. Under such condition, other proteins and enzymes will take 
up Cd2+ and therefore their functions or structures will be impaired. In another 
scenario, even in the presence of MT, there might exist some sites in some 
proteins or enzymes, which bind Cd2+ that leads to cell injury. 
 Like Zn2+, Cd2+ belongs to bio-reactive transition metal ions with filled d 
orbitals. Because of the similarity it shares with Zn2+ in its chemical properties, Cd2+ 
can mimic Zn2+ and play the role of its rival in binding to proteins and ligands in the 
cell. This simple-looking change in chemistry of cells upon their exposure to Cd2+, 
can lead to a cascade of problems in physiological activities of cells that finally 
cause kidney, lung and liver failure. Cd has a bigger atomic and ionic size than Zn. 
In comparison, this property confers higher affinity on Cd2+ toward ligands that 
have sulfhydryl groups and lower affinity toward ligands with nitrogen moieties.  
In order to study possible cellular reactions of Cd2+, we used the extracted 
proteome from rabbit liver or LLC-PK1 cells as a model. We were curious to know 
what sites Cd
2+ 
might bind to upon entrance into cells and whether apo-MT or Zn-
MT was reactive with Cd
2+ 
associated with these sites. Cd2+ was reacted with the 
proteome and after separation and purification of the product, reacted it with 
different ligands (fluorophores TSQ and ZQACID , EDTA), apo-MT, and Zn7-MT. In 
the following pages, results and explanation of these experiments are provided.  
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3.2.2. Reaction of Zn-proteome with Cd2+ 
 Zn-proteome from LL-CPK1 cells was used in this experiment. In order to 
isolate Zn-proteome from LL-CPK1 cells, cells were grown to confluence and 
harvested by scraping. Harvested cells were sonicated and centrifuged to extract 
the cell supernatant. Zn-proteome was separated from supernatant by Sephadex 
G-75 column chromatography and one-ml fractions were collected and pooled for 
analysis of its Zn2+ content. Details of these procedures are given in the chapter 2 
methods. CdCl2 was reacted with Zn-proteome for 30 min. at room temperature 
and the product solution loaded onto a Sephadex G-75 column. Collected fractions 
were analyzed for their Zn2+ and Cd2+ content by AAS. Figure 3.17a, b shows the 
chromatogram for the control proteome and sample proteome with Cd2+/Zn2+ ratio 
of 0.65. All the Cd2+ reacted with the Zn-proteome and no Zn2+ was released. The 
proteome quantatively retained both metal ions. In all reactions up to a Cd2+/Zn2+ 
ratio of 1, no Zn2+ was liberated, as indicated by the quantative retention of Zn2+ in 
the proteome and the lack of detectable Zn2+ in the low molecular weight region of 
the chromatogram. Data are summarized in Table 2.3. Clearly, Cd2+ binds within 
the proteome. Whether it reacted with Zn-containing sites could not be determined 
by this experiment. Cd2+ may have displaced Zn2+ from Zn-proteome (Cd-
proteome•Zn) or bound adventitiously to protein ligands: 
Cd
2+ 
+ Zn-proteome    Cd-proteome•Zn or   (28) 
        Zn-proteome•Cd 
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Figure 3.17a, b. Sephadex G-75 chromatography of Zn-proteome reacted with 
Cd2+. Proteome contained 120 µM Zn2+ and was reacted with 80 µM CdCl2 in Tris-
HCl buffer, pH 7.4.  
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Table 3.1. Summary of data for the reaction between the proteome and CdCl2 
 
 
3.2.3. Reaction of Cd-loaded proteome with fluorophores ZQACID and TSQ 
Two quinoline sulfonamide fluorophores; 6-Methoxy-(8-p-
toluenesulfonamido) quinoline (TSQ) and 6-Methoxy-(8-p-toluenesulfonamido) 
quinolinoxy acetate (ZQACID)) (Figure 3.18) were used to study the effect of Cd2+ 
or excess Zn2+ on metal binding properties of the proteome. Zn fluorescent sensors 
are typically comprised of a metal-chelating ligand, which is connected to a 
fluorescent moiety that undergoes a change in fluorescent properties and displays 
fluorescence upon binding of Zn2+. Studies show these fluorophores exhibit two 
distinct types of reactions with the zinc proteome [116, 128,129,131]. In one 
reaction designated as adduct formation; a ternary complex is formed with the 
participation of three moieties, the metal ion, protein, and fluorophore. In the other 
reaction, the ligand sequesters the metal ion from proteomic Zn2+ binding sites and 
a free complex of Zn2+ and the ligand with a stoichiometry of 1:2, respectively, is 
generated. Fluorescence spectroscopy of these complexes shows that upon an 
Reactants Products 
Cd2+  Zn-proteome proteome 
 Cd2+,µM   Zn2+, µM  Zn2+,µM Cd2+, µM 
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excitation at 370 nm, ternary complexes exhibit a fluorescence emission with a 
λmax at about 470 nm, whereas, free complex fluoresces with a λmax at about 490 
nm. ZQacid and TSQ quantum yields upon binding to Cd2+ are 33% those 
observed in their binding to Zn2+.  
Based on the above mentioned two different products involving TSQ and 
ZQ, possible reactions between fluorophore competing ligands (FL) and M-
proteome•Zn can be deduced as follows: 
2FL + Zn-Proteome   Proteome + Zn(FL)2    (29) 
FL + M-proteome•Zn  FL-M-proteome•Zn    (30) 
FL + M-proteome•Zn  M-proteome•Zn-FL    (31) 
2FL + M-proteome•Zn    M-proteome +Zn(FL)2   (32) 
2FL + M-proteome•Zn    proteome•Zn + M(FL)2     (33) 
2FL + M-proteome•Zn    FL•M-proteome•Zn-FL   (34) 
M=Zn2+ or Cd2+ 
FL= Fluorophore competing ligand (TSQ or ZQACID) 
TSQ alone does not react with Zn-Proteome to produce Zn(TSQ)2 and ZQ exhibits 
very small reactivity with it (≤ 5 %). TSQ and ZQ, overall, image only 10-20 % of 
the proteome Zn. In the following sections results of the reactions of TSQ and 
ZQACID with Cd-treated (Zn)-proteome will be discribed first and then results of the 
reactions between these competing ligands and Cd-treated proteome will be 
discussed. 
 
66 
 
 
1
9
 
 
 
 
 
 
Figure 3.18. Chemical structure of the two quinoline based fluorophores 6-
Methoxy-(8-p-toluenesulfonamido) quinoline (TSQ) and 6-Methoxy-(8-p-
toluenesulfonamido) quinolinoxy acetate (ZQACID)). Similarities and differences of 
these two molecules are shown. The chemical group R2 in ZQACID makes this 
fluorophore a negatively charged moiety in neutral aqueous solutions. 
 
 
 
 
 
 
 
 
 
 
 TSQ ZQACID 
R1  -H -CH3  
R2  -CH3  -CH2COOH 
R3  -CH3  -CH3  
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3.2.3.1 Reaction of Cd-loaded Proteome with TSQ 
TSQ binds to Zn2+ or Cd2+ with a 2:1 ratio of the ligand to metal. Chelation 
of the metal cation takes place by nitrogen atoms of the quinoline and sulfonamide 
groups through donation of lone pair electrons to the metal cation. Therefore, TSQ 
exhibits higher binding constant with Zn2+ in comparison to Cd2+ because it prefers 
N ligation, whereas, Cd prefers S coordination.  
Cd-treated proteome with Zn and Cd contents of 9 and 5 µM, respectively, 
was prepared and reacted with 15 µM of TSQ in 20 mM degassed Tris-HCl buffer, 
pH 7.4. The control solution consisted of Zn-proteome containing 9 µM Zn and 15 
µM TSQ in the same buffer. Fluorescence spectral increases for sample and 
control solutions were observed over the course of time for 60 minutes after which 
the final flurorescence spectrum was recorded (Figure 3.19). Sample and control 
solutions were then loaded onto G-75 columns and the collected fractions were 
measured for their metal contents (Figure 3.20a, b) and fluorescence. Reaction of 
Cd2+-treated proteome (sample) with TSQ displayed much more fluorescence 
emission when compared with Zn-proteome (control) that contained the same 
amount of metal (Figures 3.19 and 3.21). Considering that Cd(TSQ)2 has only 
about 1/3 the quantum yield as its Zn2+ counterpart, this suggests that Cd2+ 
mobilizes Zn2+ within the proteome and makes much more Zn2+ accessible to the 
fluorophore. The λmax emission for the reaction of TSQ with Cd-exposed proteome 
centered at 470 nm indicative of ternary complex formation (TSQ-Zn-proteome). 
Cd2+ reacted with the proteome without release of any significant Zn2+ (Figure 
3.17). The fluorescence spectrum indicates that many adventitious sites within the 
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proteome react with Zn2+ and TSQ to form ternary complexes. These results are 
consistent with the product of reaction- being Cd-proteome•Zn, in which both Cd2+ 
and Zn2+ are available for adduct formation with TSQ. 
 
 
 
 
Figure 3.19. Fluorescence emission spectra of Zn-proteome and Cd2+ treated 
Zn-proteome reacted with TSQ. Control solution: Proteome (9 µM Zn2+) reacted 
with 15 µM TSQ in 20 mM Tris buffer pH 7.4 in a total volume of 1 ml. Sample 
solution: Proteome (9 µM Zn2+, 5 µM Cd2+) was reacted with 15 µM TSQ in 20 
mM Tris buffer pH 7.4 in a total volume of 1 ml. Fluorescence emission spectra 
were recorded at after 60 min. with an excitation at 370 nm. 
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Figure 3.20a, b. Sephadex G-75 Chromatograms of reaction mixures for 
sample and control solutions (Figure 3.19).  
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Table 3.2. Summary of data for the reaction between TSQ and the proteome 
 
 
 
 
 
 
 
 
Control 
Reactants Products 
Zn-proteome TSQ TSQ-Zn-proteome Cd, Zn(TSQ)2 
Zn2+ (µM) 9 0 9.0 ± 0.5 (n=3) 0 
Cd2+ (µM) 0 0 0 0 
Fluoresc., 
a.u. 
(λmax, nm) 
0 0 1300 ± 50 (470) 0 
Sample 
Reactants Products 
Cd-proteome•Zn TSQ TSQ-Zn,Cd-proteome Cd, Zn(TSQ)2 
Zn2+ (µM) 9 0 9.0 ± 0.5 0 
Cd2+ (µM) 5 0 5.0 ± 0.4 0 
Fluoresc., 
a.u. 
(λmax, nm) 
0 0 4800 ± 100  (470) 0 
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3.2.3.2 Reaction of Cd-loaded Proteome with ZQACID 
In order to further investigate the phenomena taking place upon reaction of 
Cd2+ with the proteome, ZQACID was used as another specific Zn-sensor. Like TSQ, 
ZQACID binds to Zn2+ or Cd2+ with a 2:1 ratio of the ligand to metal and prefers 
binding to Zn2+ over Cd2+. Zn(ZQACID)2 displays a fluorescent emission with a λmax 
at 490 nm. ZQACID also makes ternary complexes with Zn-proteome with a λmax at 
about 470 nm [129].  
Zn-proteome containing 4.5 µM Zn2+ (as control) and Cd-treated proteome 
containing 4.5 µM Zn2+ and 3.2 µM Cd2+ (as sample) were reacted with 15 µM 
ZQACID in degassed Tris-HCl buffer pH 7.4. The fluorescence emission spectrum 
of each reaction mixture was recorded for 60 minutes (Figure 3.21a, b) using 
excitation at 370 nm. To separate proteins from low molecular weight species, 
Amicon centrifugal filtraters were employed. Sample and control solutions were 
concentrated to a very small volume using Amicon 30 kDa cut off filters and control 
and sample filtrates were collected as low molecular weight moieties and their 
fluorescence measured (Figure 3.22a, b). Tris-HCl buffer was added to restore 
control and sample concentrated proteomes to their initial volumes. Their 
fluorescence spectra were also recorded (Figure 3.23a, b). The significant 
increase of fluorescence emission from the control to the sample solution (Figure 
3.21a, b) indicates an enhanced metal availability in the proposed Cd-
proteome•Zn product for reaction with ZQACID. The dominating λmax at about 480 
nm (Figure 3.23a, b) shows that ZQ both form ternary adducts with Cd-proteome 
and also 1:2 metal to ligand complexes. The λmax emission at 490 nm for the 
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sample filtrate confirms that the sample also contained low molecular weight, free 
complex M(ZQACID)2. 
 
 
Figure 3.21a, b. Fluorescence spectra of Zn-proteome and Cd2+ treated Zn 
proteome reacted with ZQACID.   A.  Spectrum of Zn-proteome containing 4.5 µM 
Zn2+ reacted with 15 µM ZQACID in 20 mM degassed Tris-HCl buffer pH 7.4.  B. 
Spectrum of Cd2+ exposed Zn-proteome containing 4.5 and 3.2 µM Zn2+ and 
Cd2+, respectively, reacted with 15 µM ZQACID in 20 mM Tris-HCl buffer pH 7.4. 
Fluorescence emission spectra were recorded after 60 minutes with an excitation 
at 370 nm. 
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Figure 3.22a, b. Fluorescence emission spectra of the filtrate from centrifugal 
separation of control (A) and Cd2+ exposed sample (B) in figure 3.21. 
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Figure 3.23a, b. Fluorescence emission spectra of the retentates from 
centrifugal separation of control (A) and Cd2+ exposed sample (B) in Figure 3.21. 
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Table 3.3. Summary of data for the reaction between ZQACID and the proteome 
Control 
Reactants Products 
Zn-proteome ZQACID ZQ-Zn-proteome Cd, Zn(ZQACID)2 
Zn2+ (µM) 4.5 0 4.0 ± 0.4 (n=3) 0.5±0.2 
Cd2+ (µM) 0 0 0 0 
Fluoresc., 
a.u. 
(λmax, nm) 
0 0 4500 ±100 (467) 450  (492) 
Sample 
Reactants Products 
Cd-proteome•Zn ZQACID 
ZQACID-Zn, Cd-
proteome Cd, Zn(ZQACID)2 
Zn2+ (µM) 4.5 0 2.0 ± 0.3 2.5 ± 0.3 
Cd2+ (µM) 3.2 0 3.2 ± 0.2 0.0 ± 0.2 
Fluoresc., 
a.u. 
(λmax, nm) 
0 0 9400 ± 100 (470) 2100 ± 50 (492) 
 
These results confirm the finding with TSQ that upon reaction of Zn-
proteome with Cd2+, Zn2+ is labilized. In this case this is seen directly through the 
formation of Zn(ZQ)2. ZQ bind Zn2+ more strongly than TSQ. As a result, Zn(ZQ)2 
forms whereas Zn(TSQ)2 did not. Indeed, the concentration of mobilized Zn2+ is 
only 75% of the Cd2+ added to the proteome. So the Cd–Zn exchange process is 
at least semi-quantative by this measure. Interestingly, no Cd(ZQ)2 was detected 
in the filterate, indicating significant stability of Cd-proteome species.   
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3.2.4. Reaction of Cd-loaded proteome with EDTA 
Previous studies have shown that EDTA can sequester about 30% of Zn2+ 
from Zn-proteome upon 30-minute incubation with it [158]. The question is:  Does 
Cd-treated (Zn)-proteome exhibit the same behavior? Based on our hypothesis 
about the increase of Zn2+ labiality in Zn•proteome incubated with Cd2+, we 
expected a higher extent of reactivity with EDTA than seen in control Zn-proteome. 
In order to answer the question, EDTA was reacted with both Zn-proteome and 
Cd-treated (Zn)-proteome and their G-75 chromatograms were compared to reveal 
their corresponding extent of reactivity with EDTA.  Cd-treated (Zn)-proteome 
containing 44 µM Zn2+ and 22 µM Cd2+ was reacted with 86 µM EDTA in degassed 
20 mM Tris-HCl buffer, pH 7.4, 0.1 M KCl and incubated for 60 minutes before 
loading onto a G-75 column. A control solution of Zn-proteome (44 µM Zn) was 
prepared with all concentrations and conditions similar to those of the Cd-treated 
sample. Sephadex G-75 Chromatography of the reaction mixtures was carried out 
to separate proteome and EDTA. Collected fractions for both control and sample 
solutions were then analyzed for their Zn2+ and Cd2+ contents. Chromatograms 
showing metal contents of control and sample fractions obtained from the G-75 
column are depicted in Figure 3.24a, b.  Integration of chromatograms, shows 
transfer of 13 µM (30%) Zn and 26 µM Zn (60%), and 6 µM Cd (60%) from 
proteome to EDTA for control and sample solutions, respectively. The higher 
sequestration of metal from Cd-loaded (Zn)-proteome when compared to the 
control solution of native Zn-proteome, indicates a boosted lability of Zn2+ in Cd-
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exposed (Zn)-proteome. Thus, the results are consistent with proteomic Cd-Zn 
exchange reaction leading to Cd-proteome•Zn.   
 
Figure 3.24a. Sephadex G-75 chromatography of the reaction mixture of EDTA 
and Zn-proteome.  Proteome containing 44 µM Zn2+ was reacted with 86 µM EDTA 
in 20 mM Tris, 0.1 M KCl buffer, pH 7.4.  Reaction time was 60 min. 
 
 
Figure 3.24b. Sephadex G-75 chromatography of the reaction mixture of EDTA 
and Cd-loaded proteome.  Proteome containing 44 µM Zn2+ and 22 µM Cd2+ was 
reacted with 86 µM EDTA in 20 mM Tris, 0.1 M KCl buffer, pH 7.4. Reaction time 
was 60 min. 
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Table 3.4. Summary of data for the reaction between proteome and Cd-loaded 
proteome with EDTA 
Control 
Reactants Products 
Zn-proteome EDTA Zn-proteome  Zn-EDTA 
Zn2+ (µM) 44 0 31±1 (n=3) 13±1 
Cd2+ (µM) 0 0 0 0 
Sample 
Reactants Products 
Cd-proteome•Zn EDTA Cd-proteome•Zn Zn,Cd-EDTA 
Zn2+ (µM) 44 0 18±1 26±1 
Cd2+ (µM) 22±1 0 16±2 6±2 
 
 
 
3.2.5. Reaction of Cd-loaded Proteome with apo-MT 
Chelators such as EDTA, EGTA, and TPEN, regardless of their binding 
constant with Zn2+, react with proteome and sequester about 30% of Zn2+ from it 
[158]. In contrast to the above mentioned chelators, apo-MT, which has a high 
binding constant with Zn2+, has been observed to remain almost inert in the 
presence of susceptible proteome, only chelating less 0-10% of the total Zn2+. The 
above mentioned observations led us to test the reactivity of apo-MT with the 
hypothesized Cd-proteome•Zn to better understand the properties of Cd-loaded 
proteome. In this study, 4 µM apo-MT (28 µM Zn2+ binding sites) was reacted with 
Zn-proteome containing 28 µM Zn2+ (control) or Cd-proteome•Zn containing 28  
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µM Zn2+ and 23 µM Cd2+ (sample) in 10 mM Tris buffer, pH 7.4, 0.1 M KCl. After 
running sample and control solutions over a Sephadex G-75 column and analyzing 
metal content of 1 ml collected fractions, their corresponding chromatograms were 
obtained (Figure 3.25a, b, c). Integration over concentrations of Zn2+ and Cd2+ 
peaks for the HMW and LMW regions of sample and control chromatograms 
shows that in comparison with the chelation of 0-10% of Zn2+ in Zn-proteome by 
apo-MT, metal chelation increased drastically when Cd-proteome•Zn reacted with 
apo-MT. 73% of Cd2+ (17 µM) and 40% of Zn2+ (11 µM) were sequestered from 
Cd-proteome•Zn by this limiting concentration of apo-MT. These results indicate 
that upon reaction of Cd2+ with Zn-proteome, much of its Zn2+ underwent a 
rearrangement in binding sites that leads to a higher lability of Zn2+ in the proteome.  
In addition, most of the Cd2+ that had hypothetically replaced Zn2+ in native Zn-
binding sites was reactive with apo-MT. The fact that some Cd-proteome survived 
in the presence of apo-MT suggests that some Cd-proteome is stable in the 
presence of apo-MT. Thus, the results support the hypothesis that Cd2+ displaces 
Zn2+ from native Zn-binding sites in Zn-proteome to form Cd-proteome•Zn. 
m Cd-Proteome•Zn + apo-MT           m Cd(1-δ)-proteome•Zn(1-Δ) + Cdmδ-MT•Zn(mΔ) 
 (35) 
m(δ+Δ)=7    
In this equation δ, Δ parameters represent the fraction of Cd2+ and Zn2+ loss from 
Cd-proteome•Zn, respectively. m is the factor to normalize sum of δ and Δ to 7, 
which is MT capacity for Zn2+ and/or Cd2+ uptake.  
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Figure 3.25a. Sephadex G-75 chromatography of the reaction mixture of apo-MT 
and Zn-proteome.  Proteome containing 28 µM Zn2+ reacted with 4 µM apo-MT (28 
µM Zn2+) in 20 mM Tris, 0.1 M KCl buffer, pH 7.4.  Reaction time was 60 min.  
 
 
Figure 3.25b. Sephadex G-75 chromatogram of Cd-loaded proteome containing 
28 µM Zn2+ and 23 µM Cd2+. 
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Figure 3.25c. Sephadex G-75 chromatography of the reaction mixture of apo-MT 
and Cd-loaded proteome.  Proteome containing 28 µM Zn2+ ± 23 µM Cd2+  
reacted with 4 µM apo-MT (28 µM Zn2+ or Cd2+ binding capacity) in 20 mM Tris, 
0.1 M KCl buffer, pH 7.4.  Reaction time, 60 min 
 
 
Table 3.5. Summary of data for the reaction between the proteome and Cd-
loaded proteome with apo-MT 
0
2
4
6
8
10
12
14
16
0 10 20 30 40 50
M
e
ta
l,
 µ
M
Fraction Number
Zn(sample)
Cd (sample)
Control 
Reactants Products 
Zn-proteome Apo-MT Zn-proteome Zn-MT 
Zn2+ (µM) 28 0 28±1 (n=3) 3±1 
Cd2+ (µM) 0 0 0 0 
Sample 
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Cd2+ (µM) 23±1 0 6±2 17±2 
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3.2.6. Reaction of Cd-loaded Proteome with Zn7-MT 
 Based on our finding (part 3.2.1), Cd2+ reacts with the (Zn)-proteome and 
does not cause any release of Zn2+ from the proteome pool. Cd-loaded protein in 
turn exhibits more reactivity with competing ligands (parts 3.2.2-4) when compared 
to native proteome. We hypothesized that the reaction of Cd2+ with the proteome 
involved displacement of Zn2+ from Zn-proteome by Cd2+ and binding of Zn2+ again 
to the proteome. Zn-proteome and Cd-treated (Zn)-proteome were reacted with 
Zn7-MT as control and sample reactions, respectively, to test our hypothesis. 
A sample solution of Cd-proteome•Zn with respective Zn2+ and Cd2+ 
concentrations of 44 µM and 23 µM was reacted with 8 µM Zn7-MT in10 mM Tris 
buffer, pH=7.4, KCl=0.1M, in 1 ml total volume. A control solution of 1 ml Zn-
proteome was reacted with Zn7-MT under the same conditions as above. Sample 
and control solutions were run over G-75 columns equilibrated with 10 mM 
degassed Tris buffer, pH 7.4. One ml sample and control fractions were collected 
and analyzed by AAS to assess Zn2+ and Cd2+ contents. Chromatograms obtained 
for control and sample (Figure 3.26a, b, c) show that an exchange of Cd2+ and 
Zn2+ takes place between Cd-proteome•Zn and Zn7-MT. Integration of the second 
peak in Figure 3.26c for Cd2+ (fractions 22-32) indicates an uptake of about 17 
nmol by MT, equal to the concentration of 17 µM in the loaded sample. The same 
amount of Zn2+ was sequestered from Zn7-MT and was taken up by Cd-
proteome•Zn. The metal ion exchange reaction between Cd-proteome•Zn and Zn7-
MT can be shown by the following chemical equation: 
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m Cd-Proteome•Zn + Zn7-MT         m Cd(1-δ)-proteome•Zn(1+δ) + Cdmδ, Zn(7-mδ)-MT 
            (36) 
In this reaction, δ is the parameter ranging from 0-1.0 that describes the extent of 
metal ion exchange. By comparing the total amount of Cd2+ in the Cd-proteome•Zn 
with the amount taken up by metallothionein, the δ parameter in the exchange 
reaction can be obtained. The high value for δ (=0.73) is an indicative of efficient 
exchange of Cd2+ for Zn2+ in MT and Zn2+ for Cd2+ in the proteome. These results 
are consistent with the fact that the majority of intracellular Cd2+ is accumulated 
into MT.  
In vitro 113Cd NMR study on rabbit liver MT has shown a strikingly similar 
metal exchange reaction to reaction 36 between Zn7-MT and Cd7-MT [159].  
m Zn7-MT  +  n Cd7-MT             (m+n) Cd(7n/m+n),Zn(7m/m+n)-MT (37) 
This result also broadens the potential for this reaction to sequester Cd2+ in MT 
beyond an earlier Cd-Zn exchange reaction that has also seen between Zn-MT 
and Cd-carbonic anhydrase and Cd-tramtrack Zn-finger peptide [160, 161]. 
The amount of Cd2+, which stays bound to the proteome in the presence of 
MT, is hypothesized to contribute to the toxicity in cells. For example, the down-
regulation of Sp1 transcription factor activity continues even as MT synthesis is 
induced and much of the Cd
2+ 
localizes in the MT pool. In vitro, Cd
2+ 
readily 
competes with Zn
2+ 
for binding to Sp1 and in the process inhibits its ability to bind 
to SGLT1 and 2 promoter sites [162].  
84 
 
 
1
9
 
3Cd
2+ 
+ Zn
3
-Sp1              Cd
3
-Sp1 + 3 Zn
2+
     (38) 
An approximate equilibrium constant calculated on the basis of this reaction is 10, 
indicating a small preference for binding of Cd
2+ 
to the protein [80]. This probably 
reflects the stronger affinity of Cd
2+ 
than Zn
2+ 
for the two thiolate ligands in the 
binding site. Neither Zn3-Sp1 nor Cd3-Sp1 should be stable in the presence of apo-
MT. The fact that the Sp1 remains functionally down-regulated in the presence of 
induced MT is consistent with in-vitro experiments suggesting that Cd3-Sp1 
converts to Cdn-Sp1 (n=1-3) that binds Cd2+ with much larger affinity. 
 
 
Figure 3.26a. Sephadex G-75 chromatography of Zn-proteome reacted with 
Cd2+. Zn-proteome containing 44 µM Zn2+ was reacted with 25 µM Cd2+ and ran 
over Sephadex G-75 column. One-ml fractions were analyzed with AAS for their 
Zn2+ and Cd2+ content.  
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Figure 3.26b. Control Solution: Sephadex G-75 chromatography of the reaction 
of Zn-MT and Zn-proteome. Proteome containing 44 µM Zn2+ reacted with Zn7-
MT (56 µM Zn2+) in 20 mM Tris, 0.1 M KCl buffer, pH 7.4.  Reaction time, 60 min. 
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Figure 3.26c. Sephadex G-75 chromatography of the reaction of Zn-MT and Cd-
loaded proteome. Sample Solution: Proteome containing 44 µM Zn2+ ± 23 µM 
Cd2+ reacted with Zn7-MT  (56 µM Zn2+) in 20 mM Tris, 0.1 M KCl buffer, pH 7.4.  
Reaction time, 60 min 
 
Table 3.6. Summary of data for the reaction between the proteome and Cd-
loaded proteome with Zn7-MT 
Control 
Reactants Products 
Zn-proteome Zn7-MT Zn-proteome Zn-MT 
Zn2+ (µM) 44 56 44±2 (n=3) 56±2 
Cd2+ (µM) 0 0 0 0 
Sample 
Reactants Products 
Cd-proteome•Zn Zn7-MT Cd-proteome•Zn Cd, Zn-MT 
Zn2+ (µM) 44 56 60±3 38±2 
Cd2+ (µM) 23±2 0 6±1 17±2 
 
0
5
10
15
20
25
30
0 10 20 30 40
M
e
ta
l,
 µ
M
Fraction Number
Zn(sample)
Cd(sample)
C
H
3 
87 
 
 
1
9
 
3.2.7. Reaction of Zn-loaded proteome with ZQACID 
Proteome extracted and isolated from the cytosol of LL-CPK1 cells 
(containing 5.5 µM Zn2+) was reacted with 5.5 µM of Zn2+ in 20 mM degassed Tris-
HCl buffer, pH 7.4 KCl 0.1 M. The product was loaded onto a G-75 column and 
collected fractions corresponding to the high molecular weight region were pooled, 
analyzed for their Zn2+ and labeled as Zn-proteome•Zn. No free Zn2+ was detected 
in the low molecular weight region indicative of binding all Zn2+ to the proteome. 
This was further confirmed from the Zn2+ content of the pooled Zn-proteome•Zn 
(containing 11 nanomoles Zn2+).  
Zn-proteome + Zn2+             Zn-proteome•Zn   (39) 
Pooled Zn-proteome•Zn was concentrated to its initial volume of 1 ml using 
30 kDa cut off Amican filter. Zn-proteome and Zn-proteome•Zn containing 5.5 µM 
Zn2+ each, were reacted with 26 µM ZQAcid in 1 ml 20 mM degassed Tris-HCl buffer 
pH 7.4 and KCl =0.1 M as control and sample solutions, respectively. Fluorescence 
emission (excitation at 370 nm) intensity for control and sample solutions was 
recorded between 400-600 nm for about 2 hours starting immediately after mixing 
of reactants with an excitation at 370 nm. Figures 3.27a and 3.27b show control 
and sample spectra recorded over a course of 110 minutes. Fluorescence 
emission at 470 nm and 490 nm was depicted versus time in figure 3.28a and 
3.28b for control and sample solutions. Fluorescence intensities of about 5000 
units at 470 nm and 490 nm for the sample solution versus intensities of about 
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3000 units for the control solution indicate that Zn2+ was more labile and reactive 
in Zn-Proteome•Zn than in native Zn-Proteome. 
Not only the extent of reaction differs from control solution to the sample 
solution but also their kinetics of reaction are different. Contribution of the 50% 
external Zn2+ in Zn-proteome•Zn to the kinetics of the sample reaction is evident 
from kinetics analysis of control and sample reactions. A comparison of Figures 
28a and 28b shows that the kinetics of the sample reaction consists of three 
phases of reactions. However, the control reaction exhibits a biphasic reaction of 
fast and slow reactions. The phase I in the sample reaction which is totally absent 
for the control reaction, can be ascribed to to the Zn2+ added to the proteome. 
In order to have enough Zn2+ in the proteome to be detectable in atomic 
absorption spectroscopy, the above mentioned reactions were done with higher 
amounts of proteome and ZQAcid. Proteome containing 20 µM Zn2+ were used for 
this part of the experiment for both control and sample reactions. The product of 
the control and sample solutions were run over G-75 columns and 1ml collected 
fractions were analyzed for their Zn2+ and fluorescence intensities. Figure 3.29 
shows chromatograms of control and sample solutions. Integration of the Zn2+ in 
the low molecular weight region of the chromatogram shows sequestration of 12% 
and 28% of Zn2+ by ZQAcid from the control and sample proteome, respectively. 
Figures 3.30a1-b2 show the fluorescence spectrum of control and sample 
fractions recorded between 400-600 nm with an excitation at 370 nm. 
Fluorescence spectra for fractions of the high molecular regions of the 
chromatogram exhibit the characteristic λmax 470 nm indicative of adduct formation 
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and low molecular weight fractions give a λmax at 490 nm implying free complex 
formation of ZQAcid and Zn2+.  Summation of fluorescence intensities at 490 nm in 
the low molecular region of the chromatograms for the control and sample 
solutions gives similar fractional amounts of 0.12 and 0.28 of total Zn2+ 
sequestered from Zn-proteome and Zn-proteome.Zn by ZQAcid. Integration of 
fluorescence intensities for the high molecular region of the sample in comparison 
to that of the control show that adduct formation in the sample proteome is more 
facilitated and more Zn2+ can be accessed by ZQAcid for adduct formation.   
 
 
Figure 3.27a. Fluorescence spectrum for control solution of reaction between Zn-
proteome and ZQAcid. Emission spectrum with a λmax at about 470 nm and a 
shoulder at 490 nm is indicative of formation of both ZQAcid-Zn-proteome adduct 
and the free complex Zn(ZQAcid)2 in this reaction.  
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Figure 3.27b. Fluorescence spectrum for the sample solution of the reaction 
between Zn-proteome and ZQAcid. Higher fluorescence intensity for the sample in 
comparison to the control solution indicates a higher reactivity between Zn2+ from 
Zn-proteome.Zn and ZQAcid.  
 
 
Figure 3.28a. Diagram of fluorescence intensities at 470 nm versus time for the 
control reaction (Figure 3.27a). Zn-proteome containing 5.5 µM Zn2+ reacted with 
26 µM ZQAcid in 20 mM degassed Tris-HCl buffer pH 7.4.  
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Figure 3.28b. Diagram of fluorescence intensities at 470 nm versus time for the 
sample reaction (Figure 3.27b). Zn-Proteome•Zn containing 5.5 µM Zn2+ reacted 
with 26 µM ZQAcid in 20 mM degassed Tris-HCl buffer pH 7.4. 
 
 
 
Figure 3.29. Sephadex G-75 chromatography of Zn-proteome reacted with ZQ.  
Control (10 µM) Zn2+ as Zn-proteome) and Sample (10 µM Zn-proteome and 10 
µM Zn2+ reacted with 50 µM ZQ). Reaction time, 60 min.  
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Figure 3.30a1. Fluorescence spectra of the control fractions corresponding to the 
high molecular weight region of the chromatogram. 
 
 
 
 
Figure 3.30a2. Fluorescence spectra of the control fractions corresponding to the 
low molecular weight region of the chromatogram. 
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Figure 3.30b1. Fluorescence spectra of the sample fractions corresponding to the 
high molecular weight region of the chromatogram. λmax at 470 nm indicates the 
adduct formation between ZQAcid and Zn-proteome (ZQ•Zn-proteome).  
 
 
 
 
Figure 3.30b2. Fluorescence spectra of the sample fractions corresponding to the 
low molecular weight region of the chromatogram. λmax at 490 nm indicates 
sequestration of Zn2+ from the proteome by ZQAcid and the free complex Zn(ZQAcid) 
formation.  
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3.2.8. Reaction of Zn-loaded proteome with TSQ 
Zn-proteome and Zn-proteome•Zn containing 5 µM Zn2+ each, was reacted 
with 18 µM of TSQ in 1 ml degassed 20 mM Tris-HCl buffer pH 7.4 as control and 
sample solutions, rspectively. Emitted fluorescence intensity was recorded for 45 
minutes starting immediately after mixing reactants of both control and sample 
solutions. Figures 3.31a and 3.31b show fluorescence spectra recorded over 45 
minutes for control and sample solutions. Fluorescence intensities for control and 
sample reactions recorded at 470 nm are plotted versus time in Figure 3.32. 
Excitation wave length was 370 nm and fluorescence emission was recorded 
between 400 to 600 nm. Similar to the results from the reaction of ZQ with Zn-
proteome•Zn, the fluorescence intensity for the sample solution was higher than 
that of the control solution. Moreover, fluorescence spectra exhibited the 
characteristic λmax at 470 nm indicative of formation adduct complexes. The higher 
fluorescence intensities for the sample solution in comparison to the control 
solution arise from both kinetic and thermodynamic reasons. Thermodynamically, 
TSQ can compete with binding sites within Zn-proteome•Zn that bind to Zn2+ 
loosely and therefore, sequester Zn2+ and upon binding to it gives rise to higher 
fluorescence. Kinetically, there is more Zn2+ accessible for TSQ to react with and 
form adducts complexes. Three phases of reaction are deducible from the kinetics 
of the sample reaction with TSQ (Figure 3.32). About 35% of the overall reaction 
for the sample takes place in the first phase of the reaction within the mixing time.   
Control and sample solutions then were loaded onto a Sephadex G-75 
column and collected fractions were analyzed for their fluorescence intensities. 
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Figures 3.33a and 3.33b show fluorescence emission spectrum of control and 
sample fractions corresponding to the high molecular weight region of their 
chromatogram. No fluorescence emission was detected in fractions corresponding 
to the low molecular weight region of the separation profile. This observation 
implies that no detectable Zn2+ was sequestered from the proteome by TSQ either 
in control or in sample solutions. The control experiments were undertaken to 
characterize how the Zn2+ mobilized from native binding sites by Cd2+ would 
associate with the proteome as observed by ZQ and TSQ. Despite the fact that the 
amounts of Zn2+ in the native proteome and the Zn-loaded proteome were the 
same, the fluorescence response for the sample is almost three times of that from 
the control. These results confirm that the mobilized Zn2+ from the proteome 
associates with other sites within the proteome and exhibit more lability in the 
reaction with the fluorophore compared to the native sites that results in a higher 
fluorescence response.  
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Figure 3.31a. Fluorescence spectrum for the control solution of the reaction 
between Zn-proteome and TSQ. Zn-proteome containing 5 µM Zn2+ reacted with 
20 µM TSQ in 20 mM degassed Tris-HCl buffer pH 7.4, KCl 0.1 M. Fluorescence 
intensities were recorded with an excitation at 370 nm.  
 
 
 
Figure 3.31b. Fluorescence spectrum for the sample solution of the reaction 
between Zn-loaded proteome and TSQ. Zn-proteome•Zn containing 5 nanomoles 
Zn2+ reacted with 20 nanomoles TSQ in 20 mM degassed Tris-HCl buffer pH 7.4, 
KCl 0.1 M.  
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Figure 3.32. plot of fluorescence intensities at two wavelengths 470 and 490 nm 
versus time for control and sample solutions. Sample reaction displays three 
phases of reactions. 
 
 
 
Figure 3.33a. Fluorescence spectra of the control fractions corresponding to the 
high molecular weight region of the control chromatogram.  
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Figure 3.33b. Fluorescence spectra of the sample fractions corresponding to the 
high molecular weight region of the sample chromatogram. λmax at 470 nm 
indicates the adduct formation between TSQ and Zn-proteome (TSQ-Zn-
proteome).  
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3.3. The study of Zn2+ binding to the proteome using the weak Zn2+ chelating 
agent, Zincon 
3.3.1. Introduction 
The concentration of free Zn2+ in cells is not enough so that free Zn2+ is 
considered as an effective species in Zn2+ trafficking. Therefore, it was 
hypothesized that proteome bound zinc would account for such processes. The 
ligands, ZQ and TSQ that we have employed for ligand substitution reactions with 
the proteome so far had moderate to strong affinities toward Zn2+ and also readily 
form adduct species. Zincon (ZI), a colorimetric indicator of zinc, has a low Zn2+ 
binding constant and recently has been used to observe proteomic binding of Zn2+ 
[153]. From titration of HT-29 cell homogenate with Zn2+ in the presence of ZI, 
Maret and Krezel have concluded that there exists a considerable concentration 
of unoccupied Zn2+ binding sites in the cell lysate. They also hypothesized that 
such sites provide a cellular buffering capacity for Zn2+. Because of some concern, 
we revisited their experiment. In the present work, LL-CPK1 cell proteome and 
supernatant were titrated with Zn2+ in the presence of ZI. Zn-ZI was also used to 
titrate proteome, TSQ, and some model proteins such as bovine serum albumin 
(BSA), and Zn-carbonic anhydrase (Zn-CA) for further supporting information.  
3.3.2. Titration of the proteome with Zn2+ in the presence of ZI 
ZI has a weak binding affinity for Zn2+ with a binding constant of 104.9 at pH 
7.4 and 25°C. Upon binding to Zn2+, it displays an absorbance spectrum with a 
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λmax at 620 nm, characteristic of Zn-ZI species. Figure 3.34 shows chemical 
structure of ZI. 
  
 
Figure 3.34. Chemical structure of ZI. 
 
Proteome isolated from LL-CPK1 cells containing 3.2 µM Zn2+ was reacted 
with 100 µM ZI without exhibiting a significant and observable absorbance at 620 
nm. In other words, ZI did not undergo ligand substitution reaction with the 
proteome pool to sequester Zn2+ from it. In contrast, the addition of Zn2+ to 
proteome in the presence of ZI resulted in a progressive enhancement of 
absorbance at 620 nm. The titration curve consisted of two parts that qualitatively 
matched the published titration by Maret and Krezel. The first part (part I), in which 
no increase in the absorbance at 620 nm was detected, represented the initial 
phase of the titration. During this stage, ZI was unable to compete with the proteins 
that bind to Zn2+ (Figure 3.35). The absorbance increased in the second part (part 
II) of the curve; Maret interpreted this latter behavior as showing that after the 
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endpoint of part I, ZI competed efficiently with cellular binding sites to form Zn-ZI. 
But the slope of this process is substantially smaller than that obtained in the 
titration of ZI with Zn2+. Moreover, the absorbance spectra measured during the 
titration of proteome were red-shifted to 640 nm (Figure 3.36). These two 
observations suggested that the second phase of the titration of proteome was not 
simply the result of the reaction of ZI with Zn2+. 
We hypothesized that similar to some other Zn2+ chelators such as TSQ and ZQ, 
ZI forms an adduct complex with Zn2+ and proteome. 
Proteome + ZI + Zn2+       ZI-Zn-Proteome    (40) 
 The binding sites of proteome that are involved in the formation of the ternary 
adduct are those to which Zn2+ binds adventitiously. The curvature of part II of the 
titration was consistent with continued, though less powerful, binding of Zn2+ to 
proteome sites as proteome•Zn in competition with those sites that accommodated 
Zn2+ and ZI. 
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Figure 3.35. Titration of cell proteome with Zn2+ in the presence of ZI. 
Conditions: proteome containing 3.2 µM Zn2+ and 90 µM ZI titrated with Zn2+ 
in degassed Tris-HCl buffer, pH 7.4 at room temperature. 
 
  
Figure 3.36. Absorbance spectra of cell proteome titrated with Zn2+ (Figure. 
3.35) in the presence of ZI 
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In order to test this hypothesis, the product of the proteome titration was run 
over a Sephadex G-75 column. The resultant chromatogram (Figure 3.37) showed 
that proteome, ZI, and Zn2+ migrated together during the chromatographic 
separation, supportive of the hypothesis that ternary adduct formation had occured 
(reaction 40). ZI alone was also incubated with proteome for 30 min and 
chromatographed over Sephadex G-75. To detect the location of ZI in the eluate, 
5 nanomoles Zn2+ was added to each 1 ml fraction and its absorbance at 220 nm 
was measured. According to the chromatogram depicted in Figure 3.38, ZI itself 
did not associate significantly with proteome and was readily separated from 
proteome and appeared in the low molecular weight region of the elution profile. 
Thus, the presence of Zn2+ is necessary for ZI to be eluted with the proteome. In 
other words ZI is only associated with the proteome when it forms the ternary 
adducts, ZI-Zn-proteome, involving extra Zn2+ that had been added to the 
proteome.  
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Figure 3.37. Sephadex G-75 chromatography of the reaction mixture in Figure 
3.35. 
 
 
 
Figure 3.38. Sephadex G-75 chromatogram obtained from the mixture solution of 
proteome and ZI. 5 nmoles Zn2+ were added to fractions 40 to 60 to locate ZI in 
the chromatogram. 
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3.3.3. Titration of the LL-CPK1 Cell Supernatant with Zn2+ in the Presence of ZI 
The previous experiment was repeated using the entire cell supernatant that 
contained both the proteome and glutathione and similar results were obtained 
(Figure 3.39a, b). The experiment was also performed in a different way: cells 
supernatant was titrated with Zn-ZI. Upon this titration, results qualitatively similar 
to those obtained in previous experiment and depicted in Figure 3.40a, b were 
observed. At first, the spectral intensity was quenched; later as the absorbance 
increased the spectrum of Zn-ZI, characterized by a wavelength maximum at 620 
nm, was replaced by a spectrum with a shoulder at about 640 nm. 
 We hypothesized that proteome initially underwent a ligand substitution 
reaction with Zn-ZI at sites inaccessible to ZI for ternary adduct formation.  
Proteome + Zn-ZI            Zn-Proteome + ZI   (41) 
After completion of this part of the titration for this part, Zn-ZI started to associate 
with other sites to form ternary adduct complexes. This reaction was revealed by 
the shift in λmax of Zn-ZI (620 nm) to 640 nm and by a different extinction 
coefficient of the new product. 
  Proteome + Zn-ZI            ZI-Zn-Proteome   (42) 
The product solution then was chromatographed on Sephadex G-75 and the 
resulted chromatogram showed that both Zn2+ and ZI migrated with the proteome 
after completion of the titration (Figure 3.41). 
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Figure 3.39a. Titration of cell supernatant with Zn2+ in the presence of ZI. 
Supernatant containing 2.4 µM Zn2+ and 80 µM ZI titrated with Zn2+ in degassed 
Tris-HCl buffer, pH 7.4 at room temperature. 
 
 
 
Figure 3.39b. Absorbance spectra of titrating mixture in Figure 3.39a displaying a 
λmax absorbance at 640 nm 
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Figure 3.40a. Titration of cell supernatant with ZnZI. Supernatant containing 2.4 
µM Zn2+ titrated with ZnZI in degassed Tris-HCl buffer, pH 7.4 at room 
temperature. 
 
 
Figure 3.40b. Absorbance spectra of the cell supernatant titrated with Zn-ZI. The 
shoulder seen in the spectra exhibits a red-shift from the maximum absorbance at 
620 to 640 nm. 
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Figure 3.41. Sephadex G-75 chromatography of the reaction mixture in Figure 
3.40a. 
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3.3.4. Reactions of Zn-ZI with model proteins 
Several model proteins such as bovine serum albumin (BSA), carbonic 
anhydrase (CA), and trypsin were employed to further investigate the reactions of 
Zn2+ and ZI or Zn-ZI with the proteome. BSA served as a model protein with 
unoccupied Zn2+ binding sites [163]. Similar to the reaction of Zn-ZI with the 
proteome, BSA reacted with Zn-ZI and the resulted absorbance spectra exhibited 
a shift in λmax from 620 nm to 640 nm (Figures 3.42, 43). The chromatogram 
obtained from running the product solution on a Sephadex G-75 column further 
confirmed the formation of ternary adduct complex (Figures 3.44, 45). In contrast, 
two other proteins, carbonic anhydrase and trypsin did not show any reaction with 
Zn-ZI indicated by lack of change in λmax in their absorbance spectra. The former 
is a Zn-protein without unoccupied Zn2+ binding sites and the latter has neither 
Zn2+ nor documented Zn2+ binding sites. 
 
Figure 3.42. Titration of BSA with ZnZI. 16.5 µM BSA was titrated with ZnZI in 
degassed Tris-HCl buffer, pH 7.4 at room temperature 
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Figure 3.43. Absorbance spectra of the titration of BSA with ZnZI. 16.5 µM BSA 
was titrated with ZnZI in degassed 20 mM Tris-HCl buffer pH 7.4 at room 
temperature 
 
 
 
Figure 3.44. Sephadex G-75 Chromatogram of the reaction mixture of BSA and 
Zn-ZI 
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Figure 3.45. Absorbance spectra of fraction solutions (fractions 12-15) eluted in 
the high molecular part of the chromatogram shown in Figure 3.44. Any 
absorbance spectra were not   obtained in the other parts of the chromatogram. 
 
3.3.5 Model adduct formation: TSQ-Zn-ZI  
 In order to give more support to the conclusion that Zn-ZI was able to form 
ternary adducts with Zn2+ binding sites, the reaction of Zn-ZI with TSQ was 
investigated. TSQ forms ternary adducts with Zn2+ complexes and proteins 
displaying a fluorescence spectrum with a λmax emission at 470 nm [116]. Reaction 
of 0-150 µM TSQ with 30 µM Zn-ZI resulted in a fluorescent product with a 
fluorescence emission λmax at 470 nm. As more TSQ was reacted with Zn-ZI, the 
fluorescence emission spectrum was red-shifted exhibiting an emission λmax at 
490nm (Figure 3.46). The fluorescence emission λmax at 470 was ascribed to the 
ternary adduct complex that forms initially when TSQ reacted with Zn-ZI.  
 Zn-ZI + TSQ               TSQ-Zn-ZI     (43) 
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Upon addition of more TSQ and as the concentration of TSQ-Zn-ZI increased the 
following reaction occurred between these two species: 
TSQ-Zn-ZI + TSQ            ZI + Zn(TSQ)2    (44) 
As a result of the formation of Zn(TSQ)2 in reaction 42, the emission λmax shifted 
from 470 nm to 490 nm. 
 
 
Figure 3.46. Fluorescence emission spectra of the titration of 30 µM ZnZI with 15 
mM TSQ, adding 15 µM at a time in degassed 20 mM Tris-HCl buffer pH 7.4 
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4. Discussion 
Zn, the second most abundant metal in human body, plays a significant role 
in a myriad of different physiological activities as the catalytic and structural 
cofactor for thousands of enzymes and proteins [5, 6, 7].The system of chemical 
reactions in living organism that leads to cellular influx, distribution, and efflux of 
metal ions is defined as metal ion metabolism or trafficking. Chemical reactions 
that might be involved in Zn trafficking is summarized below: 
Zn2+ + p1       Zn-p1       (45) 
Zn-p1 + p2          Zn-p2 + p1 
  . 
  . 
  . 
Zn-pn-1 + pn   Zn-pn + pn-1 
Where p1 through pn-1 represent proteins that regulate Zn2+ and may consist of Zn-
transport proteins, chaperone proteins or group of proteomic sets “proteome”. Final 
set of bindings of Zn2+ to proteins occurs in Zn-pn. 
Despite the good understanding achieved during the last decade about Zn2+ 
transport into and out of the cell interior and intracellular compartments [152], our 
knowledge about the trafficking of Zn2+ to cell organelles and proteins remains 
premature. External or internal metal ions, which are chemically similar to Zn2+ 
may disrupt or interfere with the process of Zn2+ trafficking and make 
complications. We hypothesize that toxicity of heavy metal such as Cd, Pb, and 
Hg that disrupt normal physiological activities and lead to pathological conditions 
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stems from their interference with normal Zn trafficking. Cd2+ can react with 
proteins involved in Zn trafficking and impairs this important process through 
affecting normal functions of Zn proteins. 
Cd2+ + pi       Cd-pi       (46) 
i=1,..n 
We hypothesize that Cd2+ displaces Zn2+ from Zn proteins and then the displaced 
Zn2+ binds to other proteins adventitiously: 
 Cd2+ + Zn-p            Cd-p + Zn2+      (47) 
 Cd-p + Zn2+           Cd-p•Zn      (48) 
Among Zn proteins, metallothionein has been studied for more than a half 
century and its significant contribution to Zn trafficking and localization and 
disruption of heavy metal toxicity is evident [162]. Two other important participants 
in Zn trafficking and heavy metal toxicity are the cell proteome and glutathione. 
Understanding Zn2+ and Cd2+ binding and exchange properties of the above 
mentioned candidates will help better understand heavy metals toxicity and Zn 
trafficking in the cell and its compartments. 
 Metallothionein’s involvement in Zn trafficking and prevention of toxicity 
depends on its metal binding properties. Previous studies have shown that apo 
metallothionein binds to seven Zn2+ or Cd2+ with a single high binding constant of 
1011.2 and 1014.2 and forms Zn7-MT or Cd7-MT, respectively [135]. Zn7-MT and Cd7-
MT has also been observed to react with each other and form Zn, Cd-MT [79, 159]. 
These observations bring these questions to mind: how does the stable Zn7-MT 
115 
 
 
1
9
 
contribute to zinc trafficking and even more stable Cd7-MT exhibit reactivity with 
Zn7-MT? In contrast to previous studies, a relatively recent study has shown 
evidence for multi-step binding of Zn2+ to MT using the competing fluorophore 
ligand, FluoZin-3. This multi-step binding includes a low binding constant of 107.7 
for the binding of the seventh Zn2+ to MT. The authors attributed the reactivity of 
Zn7-MT and therefore its contribution to zinc trafficking to this low binding constant. 
 The reaction of FluoZin-3 with Zn7-MT was re-examined because of the 
discrepancy seen between results from the recent study and the previous studies, 
which showed concerted binding of seven Zn2+ ions to the two Zn-thiolate clusters 
in MT with a single high binding constant [135]. In our studies freshly prepared Zn7-
MT from rabbit liver (petering lab.) did not exhibit significant reactivity with FluoZin-
3 as well as ligands with weak to moderate affinity toward Zn2+ such as H2KTS and 
NTA (Figures 3.13 and 3.14). Titration of Zn7-MT with HCl also showed a single 
step pH dependent dissociation curve characteristic of a single dissociation 
constant, consistent with previous studies (Figure 3.15). 
 The high stability constant found for the binding of Zn2+ in Zn7-MT observed 
in our laboratory compared with the low binding constant for 1 Zn2+ in the protein 
used by Maret and Krezel confirmed that these proteins were different. This 
difference originates in the different methods of protein preparation conducted in 
the two groups. Maret and Krezel had prepared their Zn7-MT from an expression 
vector for human thionein, isoform 2, in E coli. Their purification process of the 
protein included step acidification to pH 1 followed by Sephadex G-25 
chromatography at pH 2 to remove all metals, followed by the addition of 7Zn2+/MT 
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at pH 7 to constitute the holoprotein. In contrast, we separated Zn7-MT from rabbit 
liver, induced using Zn2+ injections, under neutral pH conditions in all steps of the 
protein preparation. 
 We found that acidification and neutralization of Zn7-MT converts the protein 
to Zn7-MT* that shares similar Zn2+ binding properties with that from Maret’s 
laboratory. Whereas, Zn7-MT showed little reactivity with competing ligands 
FluoZin-3, H2KTS, NTA, and ZI, these ligands were able to sequester about 1 Zn2+ 
per molecule of the Zn7-MT*. Furthermore, the pH dependent titration curve for 
Zn7-MT was not reversible when titrated to very low pH, indicative of the difference 
between Zn2+ binding properties of Zn7-MT and Zn7-MT*. 
 Dissociation of Zn2+ from Zn7-MT upon acidic titration of the protein 
exhibited a smooth absorbance vs. pH curve centered at pH 4; however, re-
association of Zn2+ with apo-protein showed a two-step curve. The first step shared 
the same pattern with the dissociation reaction curve up to pH 5. The second step, 
which included 15% of the curve, laid between pH 5 and 7, and was responsible 
for the 1 Zn2+ per mole of the protein with low binding constant. Faster conversion 
of the native protein to the modified form took place at lower pH. The conversion 
reaction took 20 min or less to be completed at pH 2 or lower. However, at pH 3 
the incubation time must be extended to obtain the same extent of conversion to 
MT*. Since Zn2+ is almost or fully dissociated from the protein at pH ≤ 3 at the same 
rate, the main reaction that converts MT to MT* involves changes in the apo-MT 
structure. These changes consequently influence the subsequent re-association 
reaction of Zn2+ with modified MT* that happens as protein is restored to pH 7. 
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 Conditions for restoration of Zn7-MT* to  Zn7-MT were not found in a 
preliminary survey. Neither moderate heating nor urea treatment of Zn7-MT* 
altered its reactivity with competing ligands. These preliminary findings implied that 
some structural property of the protein backbone might change at low pH, which 
is preserved within the protein structure even after neutralization of the protein 
environment. This modification affects the protein folding about one of its two metal 
clusters. It is unknown to us what sort of structural changes might occur in the 
protein upon acidification. 
 One possibility is cis-trans isomerization of peptides bonds. The barrier 
energy for the cis-trans interconversion of X-proline (where X represents any 
amino acid) peptide bond arises from its partial double bond nature. Previous 
studies have shown that cis-trans isomerization of peptide bonds can be catalyzed 
under strong acidic conditions [164, 165]. Protonation of the carbonyl oxygen [166] 
or the amide nitrogen of X-proline peptide bond ruptures the double bond and 
favors the single bond resonance structure. The single amide bond can speed up 
the cis-trans interconversion. We hypothesize that in mild to strong acidic 
conditions (pH ≤ 3), the cis-trans isomerization of the key peptide bond along the 
protein backbone converts MT to MT*. The conserved proline 38 in the α-domain 
of MT is a candidate site for the acid-catalyzed conformational change [135, 167].  
Upon metal ion liberation under acidic conditions, MT peptide also loses its 
conformational stability, so the cis-trans interconversion reaction can be further 
facilitated. Finally, neutralization can lock the peptide bond in place as the amide-
bind undertakes its planar partial double bond character. Such an isomerization 
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could alter protein folding. Since Zn-thiolate clusters occupy the interior of each 
domain of the protein, any change in peptide folding might directly result in 
modification of one the clusters.  
 In addition to the inherent interest in the understanding of Zn7-MT* and the 
nature of its conversion and modification from Zn7-MT in vitro, it would be 
particularly significant to know if it can be formed in vivo under some other 
conditions. Examples of in vivo conformational changes under certain conditions 
are: (i) Change in configuration of His-Pro amide linkage catalyzed by protonation 
of the imidazole group near pH 7 [168] and (ii) Cis-trans isomerization of proteins 
peptide bond catalyzed by the enzyme peptidylprolyl isomerase [166]. If such 
reaction can take place in vivo, with a probable involvement of thiolate protonation, 
then Maret’s and Krezel’s argument over participation of Zn7-MT* in Zn2+ trafficking 
with companions that have a wide range of equilibrium affinities for Zn2+ may be 
physiologically relevant. This would be especially interesting considering previous 
reports suggesting presence of an unsaturated pool of metallothionein in many 
cells and the unsaturated MT could be the preferential MT species for Zn trafficking 
reactions [135, 147, 169]. 
 In terms of toxicity of heavy metals (such as cadmium and mercury) to cells, 
if one weak binding site exists in the metallothionein for Zn2+ under physiological 
conditions, there might be similar site for its counterparts Cd7-MT and Cdn, Zn(7-n)-
MT. This can imply that Cd-MT would not remain inert site of binding Cd2+ and, 
instead, contributes to the toxicity of cells. 
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Most cellular Cd2+ is bound to MT in the steady state conditions. Previous 
studies have demonstrated that cells without significant amount of MT when 
exposed to Cd2+ exhibit biosynthesis of MT after 4 hours and the majority of Cd2+ 
will be placed in the MT pool after 24h [170]. Because during the first 4 hours cells 
do not have significant amount of MT, one expects the Cd2+ will bind to other sites 
during that period and that such sites are located within the proteome. We decided 
to study the mechanism of this process in vitro and explore the role the proteome 
plays in the metal trafficking. 
We hypothesized that Cd2+ would be particularly reactive with members of 
the Zn-proteome. Reaction of Cd2+ with the proteome extracted from rabbit liver or 
LLC-PK1 cells resulted in binding of Cd2+ and mobilization of Zn2+, which remained 
non-specifically associated with the proteome after chromatographing the reaction 
mixture over sephadex G-75 column (Figures 3.17a,b). The fact that Cd
2+ 
apparently exchanged with protein-bound Zn
2+ 
under stoichiometric conditions, 
suggested that much of the Zn
2+ 
in the proteome was associated with sites that 
contained sulfhydryl ligands and prefer Cd
2+ 
to Zn
2+
 and that these sites 
thermodynamically and kinetically favor the metal exchange reaction. We 
hypothesized that the released Zn2+ binds to the proteome adventitiously and 
therefore it should be readily available for reaction with competing ligands [170].  
 If binding of Cd2+ to the proteome increases the lability of Zn2+ within the 
proteome, we should be able to test it by reacting the Cd-treated Zn-proteome with 
competing ligands. In particular, fluorescent ligands that are sensitive to Zn2+ can 
be useful for the characterization of this ligand substitution reaction.  TSQ and 
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ZQAcid bind to free Zn2+ with a ratio of 2:1 and exhibit fluorescence with a λmax at 
490 nm upon an excitation wavelength at 370 nm. Previous studies have shown 
that upon reaction of proteome with TSQ, TSQ-Zn-proteome species form. With 
ZQ, both ZQ-Zn-proteome and a small amount of Zn(ZQ)2 are generated. Reaction 
of Cd-treated Zn-proteome with TSQ and ZQAcid displayed much more 
fluorescence emission when compared with Zn-proteome (control) that contained 
the same amount of metal (Figures 3.19 and 3.21a, b). Considering that Cd(TSQ)2 
and Cd(ZQ)2 have only about 1/3 the quantum yield as their Zn2+ counterparts, this 
suggests that Cd causes a rearrangement in the distribution of Zn2+ within the 
proteome and makes Zn2+ accessible to the fluorophore. The λmax emission for all 
these reactions were centered at 470 nm indicative of ternary complex formation 
(sensor-Zn-proteome) with a shoulder at 480 nm for ZQ sensor indicative of the 
formation of both free complex species and adduct of this sensor with the 
proteome. Zn2+ reacted with the proteome without release of any significant Zn2+ 
(Figure 3.17a, b), indicative of presence of many available sites within the 
proteome to react with Zn2+ or similar metal ions; also, another confirmation for 
presence of free Zn2+ in cells with only pico molar concentrations. Similar to the 
reaction for Cd-treated Zn-proteome, Zn-proteome•Zn exhibited more 
fluorescence emission when compared to Zn-proteome, consistent with the 
hypothesis of redistribution of Zn2+ within the proteome upon reaction with free 
metal ions.  
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In vitro reaction of Zn7-MT with Zn2+, Cd-proteome exhibited a Cd-Zn 
exchange reaction (51a) similar to the Cd-Zn exchange reaction between Zn7-MT 
and Cd7-MT (51b) found earlier by Otvos et al [159].  
Cd2+ + Zn-proteome  Cd-proteome + Zn2+     (49) 
Cd-proteome + Zn2+  Cd-proteome•Zn     (50)   
m Cd-Proteome•Zn + Zn7-MT            m Cd(1-δ)-proteome•Zn(1+δ) + Cdmδ,Zn(7-mδ)-MT        
(51a) 
m Zn7-MT + n Cd7-MT           (m+n) Cdn/(n+m),Zn(7-n)/(m+n)-MT   (51b) 
The results (Figures 3.26a-c) show that the metal ion exchange reaction between 
Zn7-MT and the Zn, Cd-proteome is an efficient process. Most of the Cd2+ that was 
initially bound within the proteome accumulates in the metallothionein pool and, 
therefore, its contribution to the toxicity effects is diminished. The amount of Cd2+ 
that remains bound with the proteome would contribute to the Cd2+ toxicity. For 
example, the down-regulation of Sp1 transcription factor activity continues even 
after MT synthesis is induced and much of the Cd
2+ 
localizes in the MT pool [170]. 
Still, to the extent that reaction (51a) occurs, and proteome Cd2+ shifts to MT as 
MT Zn2+ moves to the proteome, Cd2+-Zn2+ exchange at native proteomic binding 
sites may occur and result in restoration of native function to the proteins. This 
hypothetical reaction was proposed many years ago [149]; these results provide 
encouragement for the hypothesis 
Apo-MT did not exhibit significant reactivity with the Zn-proteome. On the 
other hand, it was able to sequester both Zn2+ and Cd2+ from Cd-proteome•Zn and 
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form Zn, Cd-MT (Figures 3.26a-c). This result is in agreement with the fact that 
there exists a considerable amount of apo-MT, which can coexist with the Zn-
proteome in many cell types. And also implies that the mechanism under which 
apo-MT may acquire metal from native Zn-proteome and Cd-proteome•Zn should 
be different. In other words, the mechanism of ligand substitution reaction of apo-
MT and Cd-proteome•Zn includes sequestration of adventitously bound Zn2+ 
because of its lability. One possible route in this mechanism can be formation of 
Zn7-MT first and then Cd2+-Zn2+ metal exchange reaction between Zn7-MT and Zn, 
Cd-MT that supplies the majority of metal sites in MT pool with Cd2+.  
Apo-MT + m Cd-Proteome•Zn            Zn7-MT + m Cd-proteome•Zn(m-7)/m (52a) 
m Cd-Proteome•Zn(m-7)/m + Zn7-MT          m Cd(1-Δ)-proteome•Zn(m-7+mΔ)/m + CdmΔ-MT•Zn(7-
mΔ)             (52b) 
 To obtain more information about unoccupied metal binding sites within the 
proteome, LL-CPK1 cell lysate was titrated with ZnCl2 in the presence of ZI, which 
binds to Zn2+ with a low binding constant. The titration curve depicted in Figure 
3.35 consists of two parts. The first part, which corresponds to the addition of 10 
µM Zn2+, shows an absence of absorbance at 620 nm implying that proteome 
outcompetes ZI for binding to Zn2+. The second part of the titration curve displays 
an increasing absorbance at 620 nm upon addition of Zn2+. The y-axis intersection 
of these two parts of the curve was originally considered as the concentration of 
unoccupied Zn2+ binding sites of the proteome [153]. If ZI simply binds to Zn2+ in 
the second part of the reaction, we would expect to get a slope (extinction 
coefficient) similar to that observed in the titration of ZI by Zn2+. However, two 
123 
 
 
1
9
 
different slopes are observed. This suggests the possibility that Zn-ZI, itself, 
interacts with metal binding sites to form ZI-Zn-proteome adducts (reaction 42). 
 Zn2+ sensors such as TSQ and ZQ exhibit fluorescence emission spectra 
blue-shifted from the spectra of Zn(TSQ)2 and Zn(ZQ)2 upon reacting with the 
proteome and forming sensor-Zn-proteome adducts. To further demonstrate the 
formation of such adduct species, we conducted gel chromatography separations 
and observed that the fluorophore sensor migrated with the proteome. A similar 
approach was used to investigate the hypothesis that ZI-Zn-proteome adducts 
form during the second phase of the reaction of ZI and Zn-proteome with Zn2+. 
 Spectra of the mixture for the second part of the titration exhibited a λmax 
absorbance at 640 nm (Figure 3.36), a red-shift from the λmax absorbance for Zn-
ZI (620 nm). The red-shifted spectra suggest that the product was not Zn-ZI 
species. Sephadex G-75 chromatography showed that the absorbing product, 
containing both Zn2+ and ZI, was not free Zn-ZI species because it was eluted with 
the proteome not the small molecular weight fractions (Figure 3.37). Moreover, ZI 
that was added to the proteome was readily separated from the proteome 
indicating that the organic ligand had little affinity for proteome environments 
(Figure 3.38). The added Zn2+ was key to converting ZI into a structure that 
associated with the proteome. We hypothesized that Zn-ZI form ternary adducts 
with proteome that contains unoccupied Zn2+ binding sites. Similar results were 
obtained when supernatant was titrated with Zn2+ in presence of ZI or with Zn-ZI 
(Figures 3.39a, b). With additional evidence that Zn-ZI did not react with a model 
protein, trypsin that neither contains Zn2+ nor a documented Zn2+ binding site, the 
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hypothesis that Zn-ZI formed adducts with adventitious Zn2+ binding sites within 
proteome was strengthened. 
Because the adduct formation properties of the fluorophore, TSQ, are well 
established, its reaction with Zn-ZI was investigated. Although the hypothesized 
product, TSQ-Zn-ZI did not display a shift in its absorbance spectrum, its 
fluorescence emission spectrum was blue-shifted to 470 nm, characteristic of 
adduct complex formation (Figure 3.46). We ascribed the shift in the absorbance 
spectrum to a property coming from the interaction of Zn-ZI with the protein 
structure.  
 Next, the reaction of Zn-ZI with BSA was studied. BSA has a well-studied 
binding site for Zn2+ that might accommodate the Zn-ZI complex.  Reaction of BSA 
with Zn-ZI resulted in the formation of BSA-Zn-ZI adduct that was confirmed by the 
appearance of a red shift in its absorbance spectrum and its co-migration during 
gel chromatography (Figures 3.42-45). In contrast, two other proteins, carbonic 
anhydrase and trypsin did not show any reaction with Zn-ZI indicated by lack of 
change in λmax in their absorbance spectra. The former is a Zn-protein without 
unoccupied Zn2+ binding sites and the latter has neither Zn2+ nor documented Zn2+ 
binding sites 
 This set of findings indicates that there is a large concentration of metal ion 
binding sites within the proteome available for reaction with Zn2+ that enters the 
cell. We hypothesize that upon transport of Zn2+ from outside to inside the cell; it 
can bind to a myriad of available Zn2+ binding sites within the Zn-proteome. It does 
so in preference to GSH. Thus, Zn trafficking, the regulated movement or transfer 
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of Zn from the cell or compartment membrane to find sites of binding in Zn-
metalloproteins, may be intimately linked to the presence of the large pool of 
unsaturated Zn binding sites. The binding constants for Zn2+ binding to these sites, 
which are not comparable to those of original Zn2+ binding sites within proteome 
can facilitate transit of Zn2+ from one protein to another and contribute to Zn2+ 
regulation. Similar reactions can occur between the cell-imported Cd2+ and 
proteome. Cd2+ may first bind to the proteome adventitiously and then binds to 
specific Zn-binding sites upon Cd2+-Zn2+ exchange reactions with Zn-proteins in 
the proteome. The latter leads to an increase in the concentration of adventitiously 
bound Zn2+ to the proteome within the cell. The excess Zn2+ may be taken up by 
newly synthesized apo-MT and forms Zn7-MT. The elevated amount of Zn7-MT 
helps the cell get relieved from some of Cd2+ toxicity by taking part in an exchange 
reaction with Cd-proteome or proteome·Cd. These reactions in turn, produce Cd-
MT and restores some native Zn-proteins within the proteome.   
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Figure 4.1. Schematic Zn2+ and Cd2+ trafficking and regulation in the cell. 
 
In vivo studies on Zn2+ proteome and looking at Zn2+ proteome in individual 
organelles can expand these Zn2+ regulation studies and help better understand 
these complex processes. Further separation methods such as NSDS-PAGE and 
LA-ICPMS can be employed to look at the proteome at protein levels in the study 
of Zn2+ trafficking. Studying the proteome at protein levels will also pave the way 
to better understand the effects of Cd2+ and other toxic metals in Zn2+ regulation 
and their contribution to toxicity. 
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